Sponsored by

VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

Law The Cannabis Chronicles - Misc Cannabis News

IMO this is abject, knee jerk, PC stupidity at its best. I am so FUCKING tired of being bombarded by people's self-righteous indignation...over just about everything. sigh

Trump Comments Spark Boycott of LA Cannabis Expo

A boycott of the Cannabis World Congress & Business Expo, slated for Los Angeles in mid-Sept., started with a Facebook post on Thursday morning. By Friday afternoon it had spread to a number of prominent members of the cannabis industry.

The boycott is the latest fallout from President Trump’s comments defending white supremacists and neo-Nazis.

On Thursday, the Minority Cannabis Business Association (MCBA) put up a Facebook post announcing its withdrawal from the expo due to the presence of Roger Stone, who is booked as a keynote speaker. Stone, a self-proclaimed political dirty trickster, is a longtime mentor and advisor to President Trump, and has a long history of ugly racial incidents in his past. He’s also a vocal advocate of cannabis legalization.


RELATED STORY
Leafly Interview: Dirty Trickster Roger Stone Talks Cannabis Legalization & Trump

The MCBA posted this on Thursday: “As a result of CWC choosing this guy as their keynote speaker, MCBA has decided to withdraw from attendance and speaking roles at this conference. CWC, you know better so there’s no excuse not to do better.”

Later that day, the Cannabis Industry Journal announced that it would “no longer be a media partner of any CWCBExpo events, unless they remove Roger Stone from the keynote slot.”

The Journal editors added:

“In choosing Roger Stone to keynote, the CWCBExpo is making a Faustian bargain and we don’t believe this is right. We need to stand by our morals; the ends don’t justify the means. The cannabis industry is no place for racism and we would like to see Roger Stone removed from the keynote position at CWCBExpo.”


RELATED STORY
Kevin Sabet Takes on Roger Stone at Politicon

Scott Giannotti, a managing partner of the CWCBExpo, replied in a post addressed to Minority Cannabis Business Association leader Jesce Horton: “How convenient MCBA is promoting CWCBExpo’s biggest competitor NCIA, who hosts ALL WHITE CONFERENCES. Meanwhile CWCBExpo works hard at producing the most politically and culturally diverse conference program in the cannabis industry. But we’re racists ok lol I’ll put our show guide up against NCIA’s any day you want and show you how dumb you people are.”

That did not go over well. Wanda James, one of the most respected entrepreneurs in the cannabis industry, responded: “this is going big.”

Other leaders voicing their support for the MCBA’s position and withdrawing from the conference included Aunt Zelda’s co-founder Mara Gordon, as well as former Drug Policy Alliance California policy manager Amanda Reiman, who’s now vice president for community relations at Flow Kana.


RELATED STORY
The Haymaker: Solving the Roger Stone Dilemma

Stone’s presence has long made many cannabis activists uneasy. But he’s also been seen by some as a symbol of the common ground that conservatives and liberals can find on the issue of legalization. That uneasy alliance was shaken by Trump’s words and actions in the past week. For many, inviting a close Trump advisor like Stone to a cannabis event jumped a lane over the past seven days. What was once seen as a good-faith instance of reaching across the political aisle became a show of tacit support for Trump’s toxic views on race and violence.

Kaliko Castille summed up the feeling of many in the MCBA camp in Weed News earlier today:

“Maybe Roger Stone isn’t a racist, but you know what’s just as bad as being a racist? Using other people’s racism as a means to achieve your own political ends. There are plenty of well-intentioned conservatives that are coming around on our issue who don’t flirt with racism to make their point. If you want a principled conservative with political connections to speak at your events, invite Grover Norquist.

I don’t care how connected Stone is to Jeff Sessions or Donald Trump, if our industry decides to buddy up to people who have blood on their hands, there is no way for us to come out clean.”
 
Insofar as this article delineates some key voter sentiment on MJ, and the electorate's experience using MJ, I thought to post it here.

10 Marijuana Stats That Will Blow You Away


Love it or hate it, marijuana has been a hot topic in the U.S. and Canada over the last couple of years. Twenty-nine U.S. states plus the District of Columbia now allow legal use of medical marijuana, with eight states plus D.C. permitting recreational use of the drug. All of Canada allows legal use of medical marijuana -- and efforts are underway to make recreational use legal across the country.

But as much talk as there's been about marijuana, there are still plenty of things that many people might not realize about the status of public perception and actual use of the drug. Here are 10 marijuana statistics that will blow you away.

Image source: Getty Images.

1. 55 million Americans used marijuana in the past year
This number comes from a survey conducted by Altaba's Yahoo News and Marist College. It includes roughly 35 million adults who use marijuana at least once or twice per month and another 20 million who have used marijuana once or twice in the past year.

2. 129 million American adults have tried marijuana
A recent Gallup poll found that 45% of Americans have tried marijuana at least once. However, the Yahoo News/Marist College survey reported that 52% of American adults have tried the drug at some point in their lives. That translates to around 129 million people.

3. 83% of Americans support legalizing medical marijuana
You might have seen some polls showing that a solid majority of Americans support legalization of marijuana. The really strong support, though, is for legalization of medical marijuana. The Yahoo News/Marist College survey reported that 83% of respondents supported legalization of medical marijuana. That's consistent with another survey conducted by Quinnipiac University.

4. 13,000 kilowatts/hour of electricity used to produce 5 pounds of marijuana
Evan Mills from the Lawrence Berkeley National Laboratory in California did an analysis and calculated how much electricity was used in California's greenhouses in the production of marijuana. To put his 13,000 kilowatts figure into perspective, it's more electricity than the average U.S. household uses in a year.

5. 60 million gallons of water per day used in California's marijuana growing season
It takes a lot of water to grow marijuana. How much is 60 million gallons per day? It's 50% more than every person living in San Francisco uses.

Image source: Getty Images.

6. At least 165,000 cannabis industry workers in U.S.
Marijuana Business Daily, a publication focusing on the medical marijuana and retail cannabis industry, estimates that between 165,000 and 230,000 people work in the U.S. cannabis industry. This estimate includes employment data for retailers, wholesaler, testing labs, and ancillary companies. If the midpoint of this range is used, it means that there are more cannabis industry workers than there are dental hygienists in the U.S.

7. Around 25% fewer opioid-related deaths in states with legal medical marijuana
The opioid epidemic is a huge problem in the U.S. However, research has found that the annual rate of deaths due to opioid overdoses was nearly 25% lower in states that allow legal use of medical marijuana. Some clinical studies indicate that medical marijuana could be effective in helping to alleviate pain.

8. $655 million in tax revenue from marijuana estimated for 2017
States where marijuana is legal could generate tax revenue from marijuana totaling $655 million, according to projections by New Frontier Data. Much of this figure stems from states with legalized medical marijuana. However, politicians in states such as New Jersey are also seriously eyeing the potential to boost tax revenue from recreational marijuana.

9. $6.7 billion sales for marijuana in North America last year
Arcview Market Research estimates that the North American market for marijuana in 2016 totaled $6.7 billion. And that's 30% higher than the previous year. Arcview compares the growth in the marijuana industry to the growth of cable television in the 1990s and broadband internet in the first decade of the 21st century.

10. $37.3 billion U.S. marijuana market by 2024
How big could the U.S. marijuana market grow? According to data from Statista, within seven years it could hit $37.3 billion, including both medical and recreational marijuana markets. And this doesn't include the Canadian marijuana market, which professional services firm Deloitte thinks could generate $8.7 billion annually if efforts to legalize recreational marijuana are successful. With these kinds of numbers, expect marijuana to remain a hot topic for a long time to come.
 
Op-ed: Colorado officials should speak out on fake marijuana data used by feds
Ricardo Baca guest commentary: Most state and federal research documenting the impact of legalized marijuana show encouraging results reflecting responsible regulation


By Ricardo Baca, Denver Post Guest Commentary

Government-rooted misinformation has long been central to the very existence of War on Drugs. From government-sponsored anti-marijuana campaigns to the familiar talking points used by politicians over the decades, the Drug War has always been fueled by alleged facts that have no basis in reality.

The federal government’s misinformation campaign is still alive and well, even in these heady post-prohibition days of 2017. And it’s high time Colorado Gov. John Hickenlooper and state Attorney General Cynthia Coffman do as their counterparts in Washington state have already done and call out this misinformation for what it is: unreliable, misleading and inaccurate.

As most state and federal research documenting the impact of legalized marijuana show encouraging results reflecting responsible regulation, one federally funded agency is still producing reports that paint a very different reality.

Reports from High Intensity Drug Trafficking Areas throughout the country have inspired a successful anti-legalization campaign in Arizona, a recent USA Today op-ed under the headline “Marijuana devastated Colorado, don’t legalize it nationally” and much of United States Attorney General Jeff Sessions’ ongoing attacks on the country’s legal cannabis industry.

Related stories
The only problem: The reports are “garbage,” according to John Hudak, a senior fellow at the nonpartisan Brookings Institute who studies (maintaining a neutral position) marijuana legalization.

Hudak isn’t the only one criticizing the HIDTA reports. After Sessions penned concerned letters to legal cannabis states quoting statistics from HIDTA reports, Washington Governor Jay Inslee and state Attorney General Bob Ferguson responded sharply to the nation’s highest law enforcement official by saying the data he was using was “unreliable” and “inaccurate.”

“It is clear that our goals regarding health and safety are in step with the goals Attorney General Sessions has articulated,” wrote Inslee. “Unfortunately he is referring to incomplete and unreliable data that does not provide the most accurate snapshot of our efforts since the marketplace opened in 2014.”

Added Ferguson in his own statement: “I was disappointed by Attorney General Sessions’ letter, which relies on incomplete, inaccurate and out-of-date information on the status of Washington’s marijuana regulations.”

Ferguson later told Vice: “Misleading information does not produce good policy.”

So Hickenlooper and Coffman, I urge you to compare HIDTA’s findings with those of the Healthy Kids Colorado Survey, conducted by the Colorado Department of Public Health and Environment, and the National Institute on Drug Abuse’s Monitoring the Future study. I urge you both to compare the HIDTA data to that of the Colorado State Patrol and the state departments of Transportation and Public Safety — and ask yourself why these agencies’ data sets vary so wildly from those of HIDTA.

The HIDTA program was created by Congress in 1988 to fight drug trafficking and production, and the country’s 28 HIDTAs still do important work — including the HIDTA Heroin Response Strategy now covering 20 states through partnerships with public health agencies and public safety groups.

But as The Cannabist reporter Alicia Wallace reported earlier this month:

“The HIDTA reports … have come under criticism in the past, and the law enforcement agencies compiling them are ‘notorious for using data out of context or drawing grand conclusions that data ultimately do not support,’ Hudak said.

‘This is an inappropriate use of data from the attorney general and shows an obvious disinterest in seeking the right answer that can advance effective public policy,’ he said. ‘Instead, Mr. Sessions is committed to cherry-picking information that fit into his worldview. When it comes to Mr. Sessions and marijuana, ignorance seems to be a pre-existing condition, and he has no interest in seeking treatment for that ailment.'”

We now know the failed War on Drugs was built on a lie from the very top of our federal government infrastructure, an embarrassing chapter in American history that destroyed untold lives. And now state lawmakers have the opportunity to publicly discredit the inaccurate government-funded data that is still plaguing fact-based debates today — and in the process help their constituents better understand marijuana legalization’s actual impacts.

Now more than ever we need reliable data on the impact of cannabis legalization, and it’s your responsibilities, Hickenlooper and Coffman, to help your constituents distinguish the trusted information sources from the ideologically slanted reports described by your peers as unreliable, misleading and inaccurate.
 
Several Politicians Are Spreading Lies About Marijuana Deaths
By Joseph Misulonas | Aug 21, 2017 | Dispense, Politics


Marijuana advocates are used to misinformation being spread by the anti-cannabis crowd. They lie and say that weed is addicting, that it's a gateway drug, that it has no medical benefits, etc. But recently a handful of politicians are making up a new claim about marijuana: that it's killing people.

A series of politicians and law enforcement officials have recently pushed the narrative that drug dealers are lacing marijuana with the opioid "fentanyl," which is 50 times more powerful than heroin. They said that dealers were doing so in order to hook their users on marijuana and cause them to develop an addiction. But then it spread to politicians blaming overdose deaths on this fentanyl-laced marijuana.

The rumors seemed to begin when a coroner in Ohio blamed a string of overdose deaths on fentanyl-laced cocaine and marijuana. It then began to spread when Ohio Senator Rob Portman publicized the coroner's findings. This led to other politicians and law enforcement officials spreading the fentanyl rumors, including police officers in Ontario, various law enforcement agencies in the U.S. and a Tennessee district attorney.

The issue is that there's no evidence that this fentanyl lacing is actually occurring. Health officials in Ontario tested marijuana suspected of being laced and found no traces of the drug. Vice also ran an investigation into the rumors and consulted with multiple experts. They all said that the likelihood of finding marijuana laced with fentanyl is incredibly slim, and one former DEA official even questioned if it was even possible to do so.

Vice questioned the coroner, who said she actually hadn't seen any cases of the laced marijuana, but had been told about it from Senator Portman. It seems the source of his information was a story about "false warnings" of laced marijuana.

So a Senator took a false story about laced marijuana, pretended it was true and then began to spread it around. This is the lengths anti-marijuana people go to fight back against legalization.
 
marijuana-deaths-lies.jpg

Several Politicians Are Spreading Lies About Marijuana Deaths
By Joseph Misulonas | Aug 21, 2017 | Dispense, Politics


Marijuana advocates are used to misinformation being spread by the anti-cannabis crowd. They lie and say that weed is addicting, that it's a gateway drug, that it has no medical benefits, etc. But recently a handful of politicians are making up a new claim about marijuana: that it's killing people.

A series of politicians and law enforcement officials have recently pushed the narrative that drug dealers are lacing marijuana with the opioid "fentanyl," which is 50 times more powerful than heroin. They said that dealers were doing so in order to hook their users on marijuana and cause them to develop an addiction. But then it spread to politicians blaming overdose deaths on this fentanyl-laced marijuana.

The rumors seemed to begin when a coroner in Ohio blamed a string of overdose deaths on fentanyl-laced cocaine and marijuana. It then began to spread when Ohio Senator Rob Portman publicized the coroner's findings. This led to other politicians and law enforcement officials spreading the fentanyl rumors, including police officers in Ontario, various law enforcement agencies in the U.S. and a Tennessee district attorney.

The issue is that there's no evidence that this fentanyl lacing is actually occurring. Health officials in Ontario tested marijuana suspected of being laced and found no traces of the drug. Vice also ran an investigation into the rumors and consulted with multiple experts. They all said that the likelihood of finding marijuana laced with fentanyl is incredibly slim, and one former DEA official even questioned if it was even possible to do so.

Vice questioned the coroner, who said she actually hadn't seen any cases of the laced marijuana, but had been told about it from Senator Portman. It seems the source of his information was a story about "false warnings" of laced marijuana.

So a Senator took a false story about laced marijuana, pretended it was true and then began to spread it around. This is the lengths anti-marijuana people go to fight back against legalization.

I fucking hate politicians. Now, if we want to have hate groups in our country, can't we have one for a group that deserves to be hated...politicians?
 
One of these type bills in congress will stick eventually. Perhaps after Sessions decides to bust some state-level legal business and the rest of the politicians duck for cover from the citizen outrage and anger. Then, I bet we see those gutless bastards pass such a law.

Federal: Support the State Marijuana And Regulatory Tolerance (SMART) Enforcement Act

Congresswoman Suzan DelBene (D-WA-01) has reintroduced the State Marijuana And Regulatory Tolerance (SMART) Enforcement Act (H.R. 3534) which prohibits state-sanctioned marijuana consumers and businesses from being prosecuted by the federal government.

H.R. 3534 makes the Controlled Substances Act inapplicable with respect to marijuana law enforcement in jurisdictions that have regulated its use and distribution.

In a prepared statement, Congresswoman DelBene says that her legislation “will fix the conflict between state and federal law by giving states effectively regulating marijuana themselves, such as Washington, a waiver from the Controlled Substances Act. It also resolves the banking issues currently forcing dispensaries to operate on an unsafe, all-cash basis. These waivers will ensure people in states that have different laws than the federal government on marijuana are protected from prosecution, provided they meet certain requirements, as more and more states work to regulate marijuana in their own borders. People in these states should not live in fear of the unpredictable actions of the Attorney General and Department of Justice.”

NORML’s Political Director Justin Strekal was also quoted in Congresswoman DelBene's statement, stating, “The SMART Enforcement Act would give peace of mind to lawmakers, regulators, patients, and consumers and the 123,000 Americans who now have jobs dependent on the normalization of the lawful marijuana market.”

By a margin of more than 6 to 1, Americans say that individual states should be able to make their own laws governing the use and sale of marijuana. The SMART Enforcement Act acknowledges this voter sentiment while also ensuring states are operating in a safe and responsible manner.

Please urge your Representative to support this legislation.
 
They all said that the likelihood of finding marijuana laced with fentanyl is incredibly slim, and one former DEA official even questioned if it was even possible to do so.
I haven't heard of one case of fentanyl laced cannabis. Not one. And we all read cannabis boards. That information would be out there.

What blatant mis-information! Talk about fear mongering. And here's the real irony of the whole thing... you can get fentanyl at the drug store thanks to these same politicians who have allowed that drug to become legal and dispensed. Oh and hey.... after you drive in your car to pick up your fentanyl patches, be sure to head on over to the liquor store and the pick up your concealed weapon permit that I'm not allowed to have as well.... :mental:
 
10 States Most Likely to Pass Recreational Marijuana Next

Every week's there's a new story about how well recreational marijuana legalization has helped states such as Colorado, Washington and Oregon. And now several other states, such as California, Nevada and Massachusetts, have jumped on the train to reap the benefits of legalization. As the trend continues of states generating success from cannabis, where could we see future expansion of recreational use? Here's a list of 10 states most likely to pass recreational marijuana next.

10. New York

New York is one of the most liberal states in America. And yet, it continues to keep recreational marijuana illegal. Governor Andrew Cuomo, a Democrat, has expressed concern about smoking marijuana. Smokeable and ediblemarijuana are not available in the state's medical program. However, there remains strong support within the state to expand both the medical marijuana program and allow recreational use. Considering how powerful liberal voices are in the state, Cuomo may not be able to resist the legalization movement for long.

9. Rhode Island

Unlike many states that have legalized recreational marijuana, Rhode Island has no ballot initiative process where voters can pass laws through referendums. But, there have been several legislative attempts to legalize marijuana, and polls show that 59 percent of the state supports recreational use legalization.

8. Delaware

Delaware has an unusual relationship with marijuana. Despite allowing medicinal use, the state only has one dispensary. But the 2016 gubernatorial race seemed to indicate a changing relationship with cannabis. The Republican candidate openly supported legalization, and the Democratic candidate and eventual victor says he wants to see how legalization affected more states. That may not be a ringing endorsement, but it's definitely not a hard no to future legalization efforts.

7. Maryland

Earlier this year, a bill to legalize recreational marijuana in Maryland failed to pass the state's legislature. But this was still a positive sign for pro-marijuana groups in the state. The medical marijuana industry in the state hasn't even begun to operate yet, and already there's momentum for recreational legalization. If the rollout for medicinal cannabis is successful, that would only mean better chances for recreational use.

6. Connecticut

Connecticut's had multiple attempts to legalize marijuana for recreational use, but so far nothing has come of it. But the support is present. The state is also facing budget problems, and if those become serious enough, marijuana legalization may result simply as a matter of fiscal responsibility.

5. Illinois

The state of Illinois has been facing major budget concerns for...well...a long time. The debate is constantly raging in Springfield about how to solve the latest deficit. Marijuana has often been proposed as a possible revenue generator for the state, but it's largely been shot down, mainly due to Republican Governor Bruce Rauner's opposition. But most experts believe Rauner is facing an uphill battle for re-election in 2018, which means a new Democratic governor could take his place. And he may be more open to marijuana.

4. Missouri

Last spring, the state of Missouri allowed marijuana advocacy groups to begin collecting signatures for a bill that would both legalize recreational use of cannabis and also expand the state's current medicinal program as well. While previous signature collections have failed, advocacy groups have until May 2018 to produce enough signatures to qualify for the November 2018 elections.

3. Michigan

Marijuana advocacy groups in Michigan have tried to get recreational use on the ballot for years, but failed to collect enough signatures every time. However, this year may be different. According to state law, ballot initiatives need to collect 252,523 signatures within a 180-day window to be considered. Last month, a ballot initiative for recreational marijuana reached 100,000 signatures ahead of the advocacy group's schedule. If that trend continues you, it's 2018 may be the year Michigan legalizes recreational marijuana.

2. Vermont

Vermont has nearly made history on a few occasions by becoming the first state to legalize recreational marijuana through the state legislature rather than ballot initiative. However, every bill that's been passed ended up getting vetoed by the state's governor. After the most recent veto, the governor sent the bill back to the legislature asking for more protections on stoned driving and kids' access to marijuana. The legislature is re-working the bill, and people seem optimistic that a revised version will not get vetoed.

1. Arizona

In 2018, Arizona voters will vote on an initiative to legalize marijuana for recreational use. It's a little too early to tell if it will pass or not, but considering that's already firmly on the ballot and they can already begin generating support is a good sign.
 
Wow....what a summary. My one minor bitch is I HATE that corporate speak BS of "Takeaways". sigh. LOL

America’s Marijuana Evolution


Takeaways
The state of marijuana laws in the United States has changed appreciably over the last two decades. This rapid evolution can be tracked along five important axes:

  1. An expanding landscape of state marijuana laws;
  2. Ballooning public support for marijuana legalization;
  3. Shifting enforcement policy from the White House;
  4. Congress warming to the need for reform; and,
  5. State policymakers stepping up to support legalization without backlash.
When President Barack Obama was sworn into office, only 13 states had legalized the use of marijuana for medical purposes and none allowed its recreational use. By the time Donald Trump was inaugurated, those numbers had grown to 28 states (plus Washington, D.C.) where medical marijuana is legal and eight states (and D.C.) where recreational use is permitted. And in the months since, another state—West Virginia—passed a law legalizing medical use, Vermont’s state legislature became the first in the nation to pass a recreational legalization bill (though it was vetoed by the Governor and sent back for changes), and several other states have begun to consider their own legalization proposals. Though marijuana remains illegal at the federal level for any purpose, attitudes towards its legalization at all levels are changing, and changing quickly. In recent years, we’ve seen ballooning support in public opinion polls, substantial policy shifts in the White House, a willingness to address the issue in Congress, and state policymakers taking it up in growing numbers. As more states enact and implement legal marijuana programs, there is a growing urgency for federal policy change to ensure that states regulate as responsibly and safely as possible.

An Expanding Landscape
Since 1970, marijuana has been illegal under the federal Controlled Substances Act, listed as a Schedule I drug. That means for the purposes of federal law, marijuana has no currently accepted medical use and has a high potential for abuse—just like heroin, LSD, and ecstasy.1

At that time, marijuana was also illegal under the laws of every state. But over the last two decades, the map of state marijuana laws has undergone a significant transformation. California was the first state to legalize marijuana for medical purposes in 1996.2 Other states gradually started to follow suit, and what began as a trickle has now become a flood. In the last few years, the number of states passing laws to allow the legal use of marijuana in some form has skyrocketed.

2017_timelineAsset_1_4x-80_no_logo.png


Today, 29 states have legalized medical marijuana, eight of which also permit recreational use, and another 17 allow the limited use of non-intoxicating marijuana extracts to treat certain medical conditions (like seizure disorders in young children).3 Roughly 201 million Americans (60% of the country) currently live in states where marijuana is legal for general medical use—up from 62 million ten years ago and 32 million ten years before that. And nearly 70 million (21%) live in states where recreational use by adults is also allowed, up from 12 million in 2012 and 0 in 2011.4 All told, roughly 98% of Americans live in a state that has legalized some form of marijuana—up from 0% just 21 years ago.

Percent of U.S. population that lives in states where marijuana is legal
U.S._Population_in_States_Where_Marijuana_is_Legal.png


Change over time in numbers of Americans living in medical and recreational states
Change_over_time_edited.png


Marijuana is now legal under state laws on both coasts, in the north and south, in red states and blue states, and even in the heartland. Just last fall, Maine and Massachusetts became the first states on the east coast to legalize recreational marijuana, Arkansas became the first state in the Bible Belt to legalize medical marijuana, and the passage of a recreational legalization initiative in California will soon significantly expand the size of that market.5

State-Marijuana-Legalization-Laws-2017.jpg


At this point, all but four states in the nation have legalized some form of marijuana—all in violation of federal law. This ongoing and pervasive conflict between state and federal laws leads to some serious consequences:

  • States have to find workarounds to effectively regulate their markets, in order to avoid federal preemption suits;
  • All market participants—from dispensary owners to cancer patients—are at risk of federal prosecution and jail time; and,
  • Banks can’t safely provide services to marijuana-related businesses—even in states where those businesses are legal, forcing the market to operate in all-cash and making it difficult for states to tax and regulate marijuana businesses.
The landscape has massively shifted across the country. No longer is marijuana legalization the province of a few rogue states—it has become the new normal.

Growing Public Support
Very few issues can match the rapid uptick in public support that marijuana legalization has seen over the last two decades. Medical marijuana, in particular, is popular amongst just about every demographic group. And while support for recreational legalization lags somewhat behind that for medical, it remains well above the 50% mark and continues to rise.

Support for Medical Marijuana
Recent public opinion polls put support for medical marijuana in 2017 at 88% and 93% nationwide, which is consistent with the numbers we found in our own 2014 poll.6 Our data showed overwhelming support for medical marijuana among typically less supportive demographic groups like Republicans, women, and people of color.7 Even among those who oppose legalizing recreational marijuana, a majority support allowing its medical use.8

Support for Recreational Marijuana
Support for legalizing recreational marijuana has long lagged behind medical, but it is rapidly gaining. In 1969, only 12% of the country agreed with the statement, “the use of marijuana should be made legal.”9 That percentage had only increased to about 33% by the early 2000s.10 It wasn’t until the next decade that things really began to shift. In 2014, two years after Colorado and Washington voted to legalize recreational marijuana, public support for legalization hit the 50% mark nationwide.11 By 2017, polls clocked current support at 61% and 60%.12 The chart below from the Pew Research Center illustrates this remarkable shift over time.

Opinion on Legalizing Marijuana, 1969-2016
imagetools0.png


Note: Don't know responses not shown. Source: Pew Research Center, Survey conducted Aug. 23-Sept. 2, 201613

This increase in support for marijuana legalization is happening across age groups and political parties. Millennials remain the most supportive of legalization, with 71% in favor, but large gains have been made among older generations as well.14 According to the most recent Pew polls, 57% percent of Gen X-ers support legalization, as do 56% of Baby Boomers.15 The only age group who still opposes legalization at this point is the Silent Generation, made up of people 71 and older, among whom only 33% favor legalization.16 And while Democrats and Independents tend to be more supportive of legalization (polling in the high 60s), Republicans now only oppose it by a 7-point margin, with 46% in favor of legalization and 53% against.17 That’s a more than a 20-point increase in support among Republicans since 2010, when less than a quarter favored legalization.18 Young Republicans in particular are leading that shift: in early 2015, 63% of Millennial Republicans supported legalizing marijuana, and given the overall shift that is occurring, that number has likely grown over the past two years.19

Opposition to Federal Enforcement
Even more ardently than Americans support legalization, they oppose federal enforcement of the marijuana ban in states that have chosen to legalize medical or recreational use. A poll by CBS News in April 2017 found 71% of Americans opposed the federal government taking action to stop the sale or use of marijuana in states where it is legal—including majorities of Democrats, Independents, and Republicans.20 An April 2017 Quinnipiac poll showed similar findings, with 73% of Americans opposing government enforcement of federal marijuana laws in legal states. In fact, not a single political party, gender, education, age, or racial group supported federal enforcement of the ban where a state has legalized.21

As evident from these poll numbers, the last several decades have seen a striking shift in public opinion on marijuana legalization. Support for medical marijuana has topped off in the high eighties or low nineties. And if the current trajectory continues, support for recreational legalization can be expected to continue its exponential increase, especially if more states successfully implement legalization. It is crystal clear that no age group, gender, or political party of Americans want the federal government to send the Drug Enforcement Administration (DEA) in to raid the 46 states that have legalized some form of marijuana. It seems that on this issue, public opinion is only moving in one direction.

Shifting Federal Enforcement Policy
Unlike public opinion, federal law regarding marijuana hasn’t changed since the passage of the Controlled Substances Act in 1970—but federal enforcement of those laws has significantly evolved over time. The President, through the Department of Justice and DEA, has a great deal of control over how federal marijuana laws are enforced, especially when they conflict with the laws of a state. This wide berth has created uncertainty and a constant flow of new stances over the last two administrations, and it leaves open serious questions about what to expect from the Trump Administration on this issue.

The Bush Administration
Under President George W. Bush, the federal government strongly enforced the federal marijuana ban. While no state had yet legalized recreational marijuana, eight had legalized medical marijuana by the time he took office and five more did so before he finished his second term. During the Bush Administration, the federal government cracked down on medical marijuana dispensaries across the nation, leading to arrests, seized property, and prison sentences for dispensary operators and growers.22 DEA raids and federal prosecutions created a culture of fear that permeated the industry even in states with legal medical markets.23

The Bush Department of Justice also argued and won two major Supreme Court cases bolstering federal authority to enforce marijuana laws. In 2001, the Supreme Court upheld a broad application of the Controlled Substances Act in U.S. v. Oakland Cannabis Buyers' Coop, declaring that medical need does not create an exception to the federal marijuana prohibition.24 And a few years later in 2005, it ruled in Gonzalez v. Raich that the federal government could still enforce the federal ban in states that had legalized medical marijuana.25 Though neither of these cases overturned state laws, they did reinforce federal supremacy and made it clear that state legalization does not protect market participants from federal prosecution.26 Consequentially, growing, selling, or using medical marijuana was a risky undertaking during the Bush Administration, regardless of the state in which one lived.

The Obama Administration
President Barack Obama’s time in office saw a massive expansion of state legalization, and as the landscape shifted, his Administration rolled out a series of policy changes. As a presidential candidate, Obama pledged to roll back the aggressive enforcement polices of the Bush era, and initially upon taking office, he did so.27 In 2009, his Deputy Attorney General James Ogden released the Ogden Memo, announcing that the Department of Justice and DEA would deprioritize enforcement of the federal ban on marijuana in states where medical use was legal.28

This new policy led to rapid and wide scale growth of the medical marijuana industry—particularly in the west, where state laws and regulations were less comprehensive.29 As a result, the Administration shifted tactics in 2011, when Deputy Attorney General James Cole issued the First Cole Memorandum. Per this memo, the federal government announced it would focus its enforcement efforts against “large-scale, privately-owned industrial marijuana cultivation centers” and other similar operations, “even where those activities purport to comply with state law”—allowing the government to go after big market actors who were taking advantage of lax state laws.30 So states with strong laws like Colorado and New Mexico were largely left alone, while states like California and Montana with weak regulatory systems were returned to an era of greater federal enforcement.31

The biggest turning point for the Obama Administration and federal marijuana policy came after the 2012 election—when Colorado and Washington became the very first states to legalize the recreational use of marijuana. Rather than forcefully applying federal law in these states where voters had acted directly through ballot initiatives to legalize adult use of marijuana, the Obama Administration took steps to ensure that states choosing to legalize would prioritize federal interests in designing their regulatory systems. The Second Cole Memo, released in August 2013, laid out the federal marijuana policy that is still in place today: the federal government will not prioritize enforcement of the marijuana ban against people who are adhering to state laws—so long as those laws adequately take into account the following federal concerns:

  • Preventing distribution of marijuana to minors;
  • Preventing revenue from going to organized crime;
  • Preventing diversion to states that have not legalized marijuana;
  • Preventing commerce in other drugs;
  • Preventing violence and illegal use of firearms;
  • Preventing impaired driving;
  • Preventing unauthorized cultivation on public lands; and,
  • Preventing marijuana on federal property.32
A few months later, the Obama Administration went even further, issuing joint guidance by the Department of Justice and the Treasury Department’s Financial Crimes Enforcement Network (FinCEN) to address the banking problem.33 Banks are heavily regulated under federal law, so the conflict between state and federal marijuana laws is particularly sticky in the financial services context. Before this guidance, virtually no bank was willing to provide services or accounts to any marijuana-related business out of fear of federal prosecution for money laundering or aiding and abetting. The purpose of the new FinCEN guidance was to address this problem at least in a partial way and provide banks with some level of assurance and a process to serve the industry and move it away from all-cash operations. Like the Second Cole Memo, this guidance deprioritizes federal enforcement, this time against banks and credit unions, so long as 1) they serve only those marijuana-related businesses that are complying with state laws, and 2) none of the federal priorities laid out in the Second Cole Memo are being violated. In exchange, banks are required to perform expansive due diligence on potential clients connected to the marijuana industry and file Suspicious Activity Reports flagging all marijuana accounts for federal regulators (noting whether or not they are legal businesses in the state in which they operate).34 While this guidance opened the door to some level of marijuana banking, it fell far short of solving the problem, as it can be revoked overnight and does not provide a defense from federal prosecution.

While the Obama Administration took consequential steps to change the way the federal government enforces federal marijuana policy, none of these changes are set in stone, and none actually resolve the ongoing conflict between state and federal laws on marijuana.

The Trump Administration
The future of federal marijuana enforcement is still uncertain under President Trump. The Second Cole Memo and FinCEN guidance remain in place, but no one knows for how long. And while the President has suggested in public remarks that marijuana—or at least its medical use—should be left up to the states, his Administration has already begun taking steps that indicate hostility to state laws on this issue. Just a few months ago, then White House Press Secretary Sean Spicer said that the President sees a “big difference” between the medical and recreational uses of marijuana. He also said that when it comes to the federal marijuana ban, “I do believe you will see greater enforcement it,” particularly as it relates to recreational use.35

One major signal of this Administration’s approach to marijuana reform was naming Senator Jeff Sessions as Attorney General. As a Senator from Alabama, Sessions has long been virulently opposed to loosening marijuana laws, and he loudly criticized the Obama Administration for its use of prosecutorial discretion to limit enforcement.36 He has made a long list of statements that show deep hostility to legalization, including that “good people don’t smoke marijuana,” and marijuana is only “slightly less awful than heroin.”37 In his first few months as Attorney General, he established a task force to, in part, review the current Department of Justice policies on marijuana, asked Congressional leadership to not constrain his ability to enforce the federal ban, and wrote letters to several states that have legalized suggesting their regulatory regimes are insufficient.38 And he’s even calling for a revival of the D.A.R.E. program that was a fixture in schools in the 1980s and 90s—and that has been shown to do “little or nothing to combat substance use in youth."39

Sessions’ appointment and his actions aren’t the only signs coming out of the White House. The President himself added a signing statement to the current government funding bill reserving the right to “take care that the laws be faithfully executed” on marijuana, despite Congressional language that prohibited him from cracking down on state medical marijuana laws.40 That’s an indication that the Administration may not agree with Congress when it comes to marijuana and could potentially be planning to ignore any attempts to curtail its enforcement activities. And in May, the Administration appointed five people to its newly-created Commission on Combating Drug Addiction and the Opioid Crisis. Four of those five are on the record in strong opposition to marijuana legalization—including Chris Christie, who threatened to come after Colorado’s legal market when he ran for president in the last election; Patrick Kennedy, who co-founded the largest anti-marijuana legalization organization in the country; Charlie Baker, the Massachusetts Governor who wrote a scathing op-ed opposing the legalization ballot initiative in his state; and Bertha Madras, a former Deputy Director in the White House Office of National Drug Control Policy under the second President Bush.41

Though it has become remarkably difficult to predict the actions of President Trump and his White House, it seems fair to assume that these players will not be leading the charge on reform. Instead, any progress on resolving the conflict between state and federal marijuana laws will have to be driven by Congress.

Congress Warming to Marijuana Reform
Just as the last several decades have seen massive transformations in state laws, public opinion, and Administration policy, so too has Congress begun to shift on this issue. Despite uncertainty as to how the Trump Administration will address marijuana, support in Congress has grown markedly, especially with regard to medical marijuana. Instead of being viewed through a “tough on crime” lens, it is now commonly talked about by many on Capitol Hill as a matter of the Tenth Amendment and states’ rights. For others, marijuana reform is seen as a necessary component of criminal justice reform and efforts to reduce over-incarceration.

A Changing Atmosphere
Federal policymakers on both sides of the aisle are becoming steadily more comfortable with addressing marijuana, especially with regard to responsible regulation and increasing access to medical marijuana. Here are just a few snapshots of recent developments illustrating this change taking place on Capitol Hill:

  • The establishment of the Cannabis Caucus: For the first time ever, the 115th Congress is home to a bipartisan Cannabis Caucus, dedicated to educating Members and their staff about marijuana policy, bringing attention to the conflict between state and federal marijuana laws, and introducing bills to reform federal policy.42
  • Introduction of legislation: Two years ago, the bipartisan Compassionate Access, Research Expansion, and Respect States (CARERS) Act became the first major marijuana reform bill ever introduced in the Senate.43 Now, more than a dozen marijuana reform bills have been introduced thus far in the 115th Congress—in both the House and Senate and by both Republicans and Democrats—and many more are expected as this session of Congress continues.
  • Passage of policy riders: Though there is currently only one marijuana-related policy rider included the federal spending bill—prohibiting the federal government from enforcing the federal ban in states where medical marijuana is legal—it may soon be joined by others. Several additional riders have passed out of at least one chamber of Congress, or come extremely close, in recent years. A rider preventing the Department of Justice from enforcing the federal marijuana ban in recreational states fell only 12 votes short in the House in 2015.44 Last year, the Senate Appropriations Committee voted to prevent the Treasury Department from prosecuting banks serving state-legal marijuana businesses.45 And in 2016 both chambers passed a rider that would have allowed doctors in the Veterans Affairs system to discuss medical marijuana with their patients—but it fell out when the House and Senate versions of the appropriations bill were combined.46
  • Public statements of support and hearings: The last time the House of Representatives debated marijuana funding amendments on the Floor, at least four times as many Members—from both parties—spoke in favor of protecting state legalization from federal enforcement as spoke against it.47 And unlike in the past, when marijuana was a taboo topic on Capitol Hill, in recent years it has become a common subject of hearings in both chambers. Marijuana policy and enforcement were even specifically brought up by Senators at Attorney General Jeff Sessions’ confirmation hearing and when Deputy Attorney General Rod Rosenstein testified before the Appropriations Committee.48
  • Evolution of individual Members: It’s not just the body of Congress that’s changing on marijuana; key Members have begun to shift their positions—and thus the state of play on the Hill. Senator Lisa Murkowski (R-AK), for example, opposed marijuana legalization in her state, but when it passed by popular vote in 2014 she began to evolve. Though she would not call herself pro-marijuana, she believes it is her responsibility to the people of Alaska to make sure that legalization goes as smoothly as possible. She has since voted multiple times to limit federal enforcement in government spending bills, is co-sponsoring several Senate marijuana bills, and this spring co-authored a letter urging Attorney General Sessions to uphold the Second Cole Memo and respect state legalization efforts.49 The same shift can be seen amongst many of her peers. Everyone was surprised when long-time establishment Republican Lindsay Graham (R-SC) signed onto the Senate bill legalizing medical marijuana last Congress, but this year he’s been replaced by an even more surprising name—the very conservative Senator Mike Lee (R-UT) Add to that original co-sponsors and Democratic rising stars Senators Kirsten Gillibrand (D-NY) and Cory Booker (D-NJ), as well as libertarian firebrand Rand Paul (R-KY), and you have a who’s who of the Senate lined up to allow states to legalize medical marijuana nationwide.50
Concrete Action Instructing the Administration Not to Interfere
Though it is yet to have begun rewriting the Controlled Substances Act, Congress has very clearly spoken on marijuana policy—through the power of the purse. When Congress writes and passes appropriations bills funding the federal government, it has the ability to include restrictions that tie the hands of the Administration. That’s exactly what it’s done on marijuana with the bipartisan Rohrabacher-Farr Amendment—now the Rohrabacher-Blumenauer Amendment.

This provision amends the current government funding bill to prohibit the Department of Justice from spending any money to prevent states that have chosen to legalize medical marijuana “from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.”51 It’s a clear instruction from Congress to the executive branch not to meddle where states have legalized medical marijuana. And it’s more than just advice. In passing this amendment, Congress has instructed the Administration in no uncertain terms not to interfere—and a federal Circuit Court of Appeals reads it the same way. Per a Ninth Circuit ruling, the Rohrabacher-Farr amendment prohibits the Department of Justice not only from preventing states from implementing their medical marijuana laws, but also from raiding businesses or prosecuting people who are following the laws in their states.

First passed in 2014 by only a single vote in the Republican-controlled House, it has been included in every appropriations bill since, passing in 2015 with dozens of votes to spare, again in a Republican Congress. Every time it has passed—both on the House Floor and in the Senate Appropriations Committee—it has done so thanks to a bipartisan vote.52 And the Senate margins are even more conclusive—despite Republican majorities, the amendment passed out of committee with more than twice as many votes in favor as opposed in both 2015 and 2016. This year, the Senate Appropriations Committee passed it by simple voice vote. Unfortunately, while the amendment has been effective at protecting medical markets, it is not permanent. Because it is just a rider to a federal appropriations bill, it must be renewed each budget cycle, and is currently slotted to expire in September 2017 if Congress does not act to include it in the final version of the bill again.

Ten years ago, few Members took marijuana policy seriously, even fewer were willing to discuss it publicly, and almost none were well-versed on the problems created by the conflict between state and federal laws. But times have changed and the 115th Congress has warmed to the topic as one deserving not only serious consideration but also real action.

State Policymakers Embracing Legalization
The change that has taken place over the last decade in Washington is remarkable—but also negligible compared to what’s happening in the states. States have been steadily passing legalization initiatives, both through their legislatures and via the popular vote, since the 1990s. Of the 29 states that have legalized medical marijuana, more than half—15—did so through their state legislatures.

29 medical marijuana states, the year they legalized, and how
Ballot_v._Legislature.png


So far, each of the eight states that has legalized recreational marijuana has done so via ballot initiative. Vermont’s is the only state legislature in the nation to have passed a recreational legalization bill, but it was vetoed by the Governor earlier this year with instructions to address some specific concerns.

Once their states decided to legalize marijuana for adult use, state policymakers of both parties have endeavored to make sure legalization is implemented successfully. Earlier this year, the Governors of Alaska, Colorado, Oregon, and Washington sent a joint letter to Attorney General Sessions, defending their states’ programs and urging the Department of Justice to not intervene.53

Legislation Passing by a Wide Margin
A detailed analysis of the ten states to most recently legalize medical marijuana legislatively finds that most bills passed with large majorities, regardless of the party controlling the chamber.54 In nine of those ten states, the measure passed with at least 60% of the vote in the lower chamber of the state legislature. And in all but Ohio, the upper house voted in favor of legalization with at least 58% of the vote. In several states, the bills passed with more than 80% or even 90% approval—making it clear that medical legalization on the state level has gained wide support across the ideological spectrum.

Percent by which the 10 most recent state medical marijuana bills passed
Bill_Passage_Percentage.png


Bipartisan Support for Reform
Marijuana is even less of a partisan issue on the state level than on the federal level, though Democratic policymakers at all levels of government remain more supportive of reform than Republicans. In every single one of the ten states to most recently legalize legislatively, the majority passing the bill through each chamber of the state legislature was bipartisan. And while in nine of those ten states the Governor signing the bill into law was a Democrat, in the three most recent—Ohio, Pennsylvania and West Virginia—both chambers of the state legislature were controlled by Republicans.55 In fact, in Ohio Republican Governor John Kasich signed his state’s bill into law, making it the first to enact marijuana legalization through a process that was Republican-controlled at every stage.56 And the Democratic Governor of West Virginia who signed his state's bill into law earlier this year—Jim Justice—has since announced he is switching party affiliation to be a Republican.

Party control of the 10 state legislatures most recently passing medical marijuana laws
Party_Control.jpg


When Vermont became the first state in the nation to pass a recreational legalization bill this spring, it did so with healthy majorities as well—20-9 in the Senate and 79-66 in the House. Though only a handful of Republicans voted for the bill in each chamber, when Republican Governor Phil Scott vetoed it, he said that he is not philosophically opposed to marijuana legalization and has since been working with the legislature on a new bill that addresses some specific concerns he had raised.57

Increasingly, marijuana reform is becoming a bipartisan issue in state legislatures, regardless of the party in power. That’s especially true for medical legalization, which is now the law of the land in the majority of states.

The Lack of Backlash
We analyzed the state legislative and gubernatorial elections immediately following legalization in each of the ten states that most recently legislated medical marijuana, and we couldn’t identify a single instance of negative political consequences for elected officials who supported legalization of medical marijuana.

We could find no state legislative races in which voting in favor of a medical marijuana bill was detrimental. Only two state senates flipped party control after legalization—New York and Minnesota—but in both the medical marijuana vote had been overwhelmingly in favor and bipartisan. Only two state lower chambers flipped party control as well—Minnesota and New Hampshire—but in neither state was marijuana a major campaign issue. Not a single Governor in any of these ten states lost a reelection campaign because he or she signed a medical marijuana bill into law—in fact, only one Governor lost their reelection at all (Democrat Pat Quinn of Illinois), and it was to an opponent who did not oppose medical marijuana legalization.

It seems clear that legalizing medical marijuana is not a political liability for Governors or state legislatures. In fact, given the overwhelming popularity of medical marijuana, just the opposite may prove to be true going forward, especially as more states legalize and those that don’t are left behind.

State policymakers have led the way on marijuana reform. More than half of the 29 states that have legalized medical marijuana did so legislatively, and more are likely to follow. The growing bipartisan nature of state reforms and the absence of any major political consequences for those policymakers who enacted them illustrate that policymakers can feel comfortable publicly supporting legalization, regardless of party affiliation.

Conclusion
The policy landscape has changed dramatically around marijuana during the past 20 years. Roughly 98% of Americans live in states that permit some use of medical marijuana and roughly one-fifth of the country’s population lives in states where recreational use is also legal.58 Public support for legalization—and opposition to federal enforcement—is at the highest levels ever seen. And while there is uncertainty about what course the Trump Administration will take on marijuana policy, support in Congress and statehouses nationwide continues to grow. Increasingly, federal policymakers are recognizing the conflict between state and federal laws and are working to proactively to address it. That’s critical, because as the number of states where marijuana is legal expands, the need for responsible, safe, and smart governance is more important than ever.
 
Great article. Makes me a bit ashamed of our close minded, antediluvian US government policies. Well worth reading, this is where MJ research is really going on.


How the Booming Israeli Weed Industry Is Changing American Pot


U.S. medical marijuana companies are setting up shop in Israel, where fewer roadblocks mean better research – and faster results

Standing on the rear balcony of a gray factory building off the side of a highway, Tamir Gedo shields his eyes from the blazing sun. He points to the 23 acres of agricultural fields spread out before him. "We'll be able to produce more cannabis here than the entire state of Colorado," he says. Minutes later, walking past the 8,000 square-foot storage room, he adds, "We can store enough in this warehouse to supply medical marijuana for the whole United States.

With one million square feet of cultivation fields, a 35,000-square-foot production plant, and 30,000 square feet of grow rooms and labs, Gedo's company, Breath of Life Pharma (BOL), is about to open the world's largest medical marijuana production, research and development facility. According to Gedo's estimates, BOL will produce 80 tons – more than 175,000 pounds – of cannabis per year.

A tour of BOL's new facility feels like a walk through the medical-marijuana version of Willy Wonka's Chocolate Factory. With its patented extraction and purification equipment, grow rooms and germination labs, BOL will be pumping out pharmaceutical-grade cannabis tablets, capsules, inhalers and oils that are customized to treat certain ailments, with specific and controlled consistencies.

And no, this isn't happening in Colorado, California, or anywhere near America for that matter. This medical weed wonderland sits in what might be the last place you would imagine finding the world's largest facility for medical marijuana: Israel.

Over the past 50 years, Israel has become the epicenter of medical pot. Home to Raphael Mechoulam, the pioneer of marijuana research, Israel is where THC and the endocannabinoid system were first discovered. And with the world's largest number of clinical trials testing the benefits of medicinal cannabis, Israel has become the global destination for medical cannabis research and development. Now it is becoming the offshore greenhouse for American cannabis companies seeking to overcome the federal roadblocks standing in their way.

Israel was among the first countries to legalize medicinal use, and is one of just three countries with a government-supported medical cannabis program. Though recreational use remains illegal, support for legalization is a bipartisan issue, with some of the most outspoken proponents coming from the right. Until now, Israel's role in this multi-billion dollar field has been limited to R&D. Yet now that the Israeli government has approved the export of medicinal cannabis products, companies there are hoping to gain a larger piece of the market. While importing cannabis into the United States is illegal under federal law, companies can get around that ban by receiving drug approval from the FDA – and that is exactly what Israeli companies hope to do. According to the FDA, nothing is stopping them, as long as they meet the agency's arduous requirements for drug approval.

gettyimages-517697176-1c03daa9-2497-4c0f-8ae3-9e9bfccbcc79.jpg

Breath Of Life Pharma says it will produce 80 tons – more than 175,000 pounds – of cannabis per year. Jack Guez/AFP/Getty
While the FDA has approved three drugs containing synthetic cannabinoids (Marinol, Syndros and Cesamet, which treat symptoms of AIDS and chemotherapy), it has never approved a product derived from botanical marijuana. According to the agency's guidelines, "Study of marijuana in clinical trial settings is needed to assess the safety and effectiveness of marijuana for medical use." Yet initiating clinical trials on U.S. soil is difficult to the point of being nearly impossible. So, American companies are increasingly taking a shortcut: beginning phases 1 and 2 of their clinical trials in Israel, after which they will complete phase 3 in the U.S., speeding up the process through which they can apply for FDA approval of the botanical cannabis drugs they are developing.

Though this level of American R&D in Israel is new, Israel's impact on the American cannabis industry is not. The very fact that medical marijuana is now legal in 29 U.S. states and counting, is a direct result of Israeli research, which essentially legitimized the study of cannabis in the international scientific community that had long stigmatized it. Without this research, "We wouldn't have the scientific interest we have now around the world," says Paul Armentano, deputy director of the D.C.-based National Organization for the Reform of Marijuana Laws (NORML). "That really opened the door to making the study of cannabis and cannabinoids a legitimate avenue for more conventional scientists and researchers."

"The seriousness with which the Israeli scientific community approaches this is incomparable," says Charles Pollack, director of the Lambert Center for the Study of Medicinal Cannabis at Thomas Jefferson University in Philadelphia. "Israel is a hotbed of quality cannabis research, because they have a much more favorable regulatory climate for doing serious scientific research on medical cannabis."

Israel is becoming the offshore greenhouse for American cannabis companies seeking to overcome the federal roadblocks.
The Lambert Center is one of several American institutions that have partnered with BOL, collaborating on at least one of the more than 50 clinical trials the Israeli company will begin once its new facility is fully operational in late September. Of the 15 international companies that have already signed up to conduct their R&D at BOL's facility, at least six are American, and Gedo is in talks with more.

BOL isn't the only Israeli cannabis company benefitting from international interest. A growing number of American investors are getting on the Israeli cannabis wagon, which they see as the best vehicle for transforming the medical cannabis field, still in its infancy, into a pharmaceutical-level industry.

According to Saul Kaye, the founder of iCAN, an Israeli cannabis R&D firm, 2016 saw the investment of more than $250 million in Israeli cannabis companies and startups – half of that investment came from North America. Kaye predicts that investment will grow ten-fold over the next two years, reaching $1 billion. At least 50 American cannabis companies – and counting – have established R&D operations in Israel.

Israel's journey to the forefront of the medical cannabis field began with 86-year-old Israeli chemist Raphael Mechoulam, known in the field as the Grandfather of Medical Marijuana. In 1963, as a young researcher, Mechoulam secured 11 pounds of Lebanese hashish, which had been confiscated by his friend at a police station in Tel Aviv. He used that hash to identify, isolate and synthesize THC, the psychoactive compound in cannabis, for the first time in history, and study its medical uses. He was also the first to decode the structure of CBD, the plant's primary non-psychoactive ingredient. But Mechoulam's most groundbreaking discovery came in 1992, when he and his team at Hebrew University in Jerusalem discovered the physical reason humans can get high.

1037932-a88eb3dd-ffa1-429d-940c-925e85120519.jpg

Raphael Mechoulam discovered THC and the endocannabinoid system, opening up the field of medical marijuana. Hebrew University/Raphael Mechoulam
"It turned out that the cannabinoids in the plant actually mimic the compounds that we form in our brain," says Mechoulam, a professor and researcher at Hebrew University who works with several American cannabis companies. He and his team discovered that THC triggers the human body's largest receptor system, now known as the endocannabinoid system, and that the human brain produces its own cannabinoids – compounds that stimulate the body almost exactly the way THC does.

While Mechoulam's research is what first placed Israel on the medical marijuana map, the country's progressive attitudes toward cannabis, coupled with the Israeli government's liberal regulatory policies and the nation's technological leadership, are what have maintained Israel's status as the capital of medical marijuana research and development. It might also help that Israel has the world's highest ratio of marijuana users, according to Israel's Anti-Drug Authority, with 27 percent of the population aged 18-65 having used marijuana in the last year. That rate is followed by Iceland and the U.S., at 18 and 16 percent respectively.

While the Israeli government invests millions of dollars in medical cannabis research, the U.S. government makes the same research nearly impossible.

"There are onerous restrictions on conducting this research in the U.S. that don't exist in Israel," says one expert.
Despite the fact that 95 percent of the U.S. population lives in states where cannabis is legal in some form, marijuana remains federally illegal. This policy makes conducting research into the medical benefits of marijuana notoriously difficult on U.S. soil. Researchers who wish to do so must go through the DEA, the FDA and the National Institute on Drug Abuse (NIDA). Even when American researchers are given approval, they have only one source for their material: a cannabis farm at the University of Mississippi, operated by NIDA. The process, if successful, can take years.

"There's a lengthy and arduous regulatory process for getting approval for doing studies, and limited resources at these agencies for processing those requests," says Pollack, of Thomas Jefferson University. "It's deliberately made very difficult for us." In Israel, on the other hand, a cannabis clinical trial can get off the ground in a matter of months.

"I think they have approached the issue in a more even-handed and genuine way than the U.S. government has," says Armentano of NORML. "There are onerous restrictions on conducting this research in the U.S. that don't exist in Israel."

This is precisely why many American researchers from universities and private companies are using Israel as an offshore research hub. For example, Pollack, from Thomas Jefferson University, will be conducting clinical trials at BOL's new facility. Since the trials haven't begun, he won't divulge details, but says they will focus on orphan drug indications, meaning they will be testing the benefits of cannabinoids on people with diseases that don't afflict many people in the U.S. (It also means that the clinical studies are smaller – and go faster – given that fewer patients are needed for these trials.) For that reason, he said, "Big pharma companies tend not to pursue them because there's not a big enough market for these drugs."

gettyimages-517696970-3a367a0f-dbbc-431e-ad46-543b67597e43.jpg

The treatments coming out of BOL will be derived from marijuana plants – but they won't be the plants themselves. Jack Guez/AFP/Getty
Kalytera – a California-based company with a lab in northern Israel and Mechoulam on its scientific advisory board – is also focusing on orphan drug indications, conducting clinical trials at Israeli clinics and hospitals in order to bring to market a cannabinoid drug for the treatment of graft-versus-host-disease, which can happen after certain kinds of transplants.

What institutions like Kalytera and Thomas Jefferson University do is they conduct the initial phases of their clinical trials in Israel, since it's much easier to get the process started here, and then they do the final stages in the U.S., since FDA approval requires that part of the study be done there. Once they reach the final stage (phase 3) it's much easier to conduct the rest of their study in the U.S., because they've already amassed enough data to show that it's safe. This is the ultimate goal for Kalytera, Pollack and other researchers in Israel: to speed track the process of conducting a clinical trial that meets FDA standards, thus shortening the journey toward FDA approval of their drugs.

In addition to Kalytera, Mechoulam works with two other American companies, helping them develop new cannabinoid drugs and delivery methods out of his lab in Jerusalem, where he tests the specific properties, compositions and combinations of the cannabis compounds that are best suited to alleviate a specific ailment. American companies then use that research and data to manufacture cannabinoid drugs in the U.S.

According to Saul Kaye of iCan, about 50 U.S. cannabis companies are conducting research in Israel through partnerships, joint ventures or by employing Israel-based researchers like Mechoulam. At least 15 American cannabis companies have set up their entire R&D operations on Israeli soil, conducting clinical trials, and developing the appropriate dosing forms and delivery systems for pharmaceutical-grade cannabis-based drugs. According to Michael Dor, senior medical advisor at the Health Ministry's cannabis unit, at least 120 clinical trials are currently under way in Israel to test the medicinal benefits of cannabis — more than any other country.

At least 15 American cannabis companies have set up their entire R&D operations on Israeli soil.
Cannabics, a Maryland-based, publicly-traded company, is conducting a clinical trial at an Israeli hospital in order to develop a capsule for cancer treatment. In 2015, One World Cannabis Pharmaceuticals, a public company based in Delaware, established an Israeli subsidiary overseen by Yehuda Baruch, the first head of the Israeli government's medical cannabis program, established in 2007. They are now beginning phase 1 of a clinical trial to test the benefits of a topical cannabis cream to treat psoriasis. Their next trial will study the efficacy of a soluble pill for the treatment of chronic pain. They eventually plan to conduct clinical trials on patients with multiple myeloma.

Some Israeli companies have partnered with American companies to establish a presence in the U.S., where they sell products that were developed in Israel. For example, Tikun Olam, Israel's first medical cannabis distributor, opened an American subsidiary in 2016. It now sells its proprietary medical-grade plant strains at 10 dispensaries in Delaware and Nevada and will soon be available at dispensaries in Oregon and California. Their most popular strain is Avidekel, a non-psychoactive CBD blend used to help children with seizures.

Some American researchers have even moved to Israel all together. Alan Shackelford, a Harvard-trained physician, was among the first American doctors to prescribe cannabis to a child. His eight-year-old epileptic patient Charlotte Figi sparked national interest in CBD after her miraculous story aired on CNN's Weed documentary in 2013.

Yet after years of failed attempts to conduct clinical trials in the U.S., Shackelford recently established his own research entity in Israel because of his frustration with the American government's stonewalling.

"The U.S. government has funded $1.4 billion in marijuana research since 2008," says Schackelford. "Yet $1.1 billion of that went to studying addiction, withdrawal and drug abuse," problems that barely exist with cannabis when compared to the effects of other legal medications, like prescription painkillers, which killed more than 17,000 Americans in 2016.

His research subjects in Israel will include the development of new delivery methods, he says, "because to date, most medical cannabis products no matter where you look in the world, are pot-culture derived. They're things like brownies, cookies, candy and smoking. Even with advances to these things being much more consistent, they're still not medically appropriate."

While the U.S. government restricts American cannabis companies on U.S. soil, it does not prevent them from or penalize them for conducting their work in Israel. According to Robert Farrell, president of Kalytera, "The FDA has no problem with this work being done in Israel. When you file with the FDA, in the application you say, 'Look we've done the previous studies in Israel, gave the drug to this many patients, the drug is safe, it works, now we want to conduct a larger study with patients in the U.S.' If the FDA is satisfied with the data, they'll say, 'Go ahead, try it in the U.S.'"

The FDA will never get behind cannabis the plant as medicine, since it can't be controlled as a consistent drug.
Even the National Institutes of Health (NIH) has funded cannabis research in Israel. Indeed, much of Professor Mechoulam's groundbreaking research was funded by the American government. The NIH provided him with grants to the tune of $100,000 a year for over four decades, says Mechoulam.

There is also nothing preventing Israeli companies from receiving FDA approval for their cannabis-based drugs, as long as they meet FDA requirements. In order to do so, they will need to develop the kind of products that are more in line with pharmaceutical standards, such as the kinds of capsules and inhalers BOL is developing.

While that goal is feasible, Gedo and others admit that it will take time, perhaps several years, to achieve. The process of getting FDA approval is an arduous one, especially for a drug that has long been viewed with skepticism by the medical establishment. Yet it is these clinical trials that are taking place at a record pace in Israel, along with the advancement of pharmaceutical grade cannabinoid drugs, that will enable Israeli companies to eventually receive FDA approval for their drugs, or for the drugs that they are helping American companies to develop.

As Gedo notes, the FDA will never get behind cannabis the plant as medicine, since it can't be controlled as a consistent drug that has the same effect day in and day out. After all, there are 140 active compounds in cannabis, and the composition of the flowers plucked from one branch can fluctuate wildly, by up to 300 percent. "The experience of a user will vary a lot with the same strain," says Gedo. "So even if you have the best-grown product, it will never become a scientific pharmaceutical product."

This is precisely why the FDA has never approved a botanical marijuana drug, a larger problem than scheduling when it comes to drug approval. According to Senate testimony by the FDA's Douglas Throckmorton in 2016, in order to obtain FDA approval, drug manufacturers "must demonstrate that they are able to consistently manufacture a high-quality drug product. This is an essential part of drug development and presents special challenges when the drug is derived from a botanical source, such as marijuana…. If there is any future for marijuana as a medicine, it lies in its isolated components, the cannabinoids and their synthetic derivatives."

BOL and other Israeli companies are working to meet that challenge by developing cannabis-based drugs – the capsules, inhalers, creams and oils composed of isolated, controlled and consistent cannabinoids. Going this route, they could eventually receive FDA approval.

While Gedo is optimistic, he's also realistic, knowing the complexity of the FDA's drug approval process, and the skepticism that remains among many in the medical establishment.

Still, asked when Israeli companies might be exporting their cannabis medicine to the U.S., Michael Dor, of the Israeli Health Ministry says, "I believe it's not far."
 
Can it get any more ludicrous?

Pot Was Flying Off the Shelves in Uruguay. Then U.S. Banks Weighed In.

The pharmacies selling pot were doing a brisk business.

After Uruguay became the first country in the world to fully legalize marijuana sales for recreational use last month, some of the pharmacies struggled to keep up with the demand.

Then came the stern letters from American banks.

The letters immediately sent officials in Uruguay scrambling to make sense of the Patriot Act and other American laws that could doom an essential part of their country’s new pot market.

American banks, including Bank of America, said that they would stop doing business with banks in Uruguay that provide services for the nation’s state-controlled marijuana sales.

Afraid of losing access to the American banking system, Uruguayan banks warned some of the pharmacies over last couple of weeks that their accounts would be shut down, potentially signaling a broader international impasse as other countries, including Canada, set out to legalize marijuana.

“We can’t hold out false hope,” President Tabaré Vázquez of Uruguay told reporters this week, adding that his administration was trying to come up with a solution.

The snag mirrors challenges that pot businesses have faced in American states that have legalized medical and recreational cannabis. Under the Patriot Act, which was passed weeks after the Sept. 11 attacks, it is unlawful for American financial institutions to do business with dealers of certain controlled substances, including marijuana. The provisions were designed to curb money laundering and drug trafficking.

The Obama administration indicated in 2014 that banks were unlikely to face penalties for offering services to marijuana businesses in states where the trade is legal, as long they screened accounts for signs of money laundering and ensured that customers followed state guidelines. This enabled some pot businesses to get bank accounts from credit unions, but major banks have largely stayed away from the expanding pot industry, concluding that the burdens and risks of doing business with marijuana sellers was not worth the hassle.

“Banks are businesses, and they can pick and choose who they do business with,” said Frank Robison, a lawyer in Colorado who specializes in marijuana regulation. “From a banking industry perspective, the marijuana industry might be perceived as a flea on a dog’s back.”


uruguay3-master675.jpg


American banks, including Bank of America, said they would stop doing business with banks in Uruguay that provide services for the country’s state-controlled marijuana sales. Credit Spencer Platt/Getty Images
Several pot businesses in states like Colorado and Washington — the first to legalize recreational marijuana — have opted to remain cash-only businesses. Others have found small banks willing to take a calculated risk.

But finding a workaround in Uruguay may be hard. Pot sales represent a small share of business for pharmacies, which are currently the only businesses licensed to sell marijuana, and the pharmacies say they need banking services to operate.

Similarly, bankers in Uruguay will probably find it much more important to remain in good standing with American financial institutions than preserving the accounts of a small number of pharmacies.

The threat of losing their bank accounts has led some of the roughly 15 pharmacies that initially signed up to participate in the new market to give up on marijuana sales, said Pablo Durán, a legal expert at the Center of Pharmacies in Uruguay, a trade group. Another 20 pharmacies that were expected to join the market are holding off while the government explores solutions, he said.

The American regulations are counterproductive, supporters of the legal market in Uruguay contend, because they may inadvertently encourage, not prevent, illicit drug sales.

Fighting drug trafficking was one the main reasons that the Uruguayan government gave for legalizing recreational marijuana. Officials spent years developing a complex regulatory framework that permits people to grow a limited supply of cannabis themselves or buy pot at pharmacies for less money than the black market rate, providing a legal structure that lawmakers hoped would undercut illicit marijuana cultivation and sales.


“There probably isn’t a trade in Uruguay today that is more controlled than cannabis sale,” Mr. Durán said.

As a candidate, President Trump said that American states should be free to chart their own course on marijuana, and he promised to pare back regulation in the financial sector. Attorney General Jeff Sessions, however, has been a sharp critic of legalization and has compared pot to heroin.

Now, some members of the pot industry wonder whether the United States government will resolve the conflict between its banking laws and the expanding patchwork of pot legalization measures for recreational and medical use around the world. The guidance from the Obama administration, issued by the Justice and Treasury Departments in a pair of memos in 2014, addressed the matter domestically but not for international banking.

Photo
uruguay2-master675.jpg


Buying marijuana in a pharmacy in Montevideo. Credit Andres Stapff/Reuters
“Uruguay may be the tip of the iceberg,” said Mr. Robison, the Colorado lawyer who specializes in marijuana regulation.

Pharmacists in Uruguay were incredulous to learn that their bank accounts could be shut down, considering the years of study and planning that preceded the start of retail marijuana sales last month. The country’s marijuana law was passed in 2013.

“We can’t understand how the government didn’t have the foresight to anticipate this,” said Gabriel Bachini, a pharmacy owner in the coastal city of Colonia.

Since sales began, the number of registered buyers in Uruguay has more than doubled. As of Aug. 15, more than 12,500 people had enrolled in a system that verifies customers’ identity with fingerprint scanners and allows users to buy up to 40 grams of marijuana per month (at a price of about $13 dollars for 10 grams, enough for about 15 joints, advocates say). Under the law, only Uruguayan citizens and legal permanent residents are allowed to buy or grow pot.

“Demand has been very strong,” Mr. Bachini said. “People are thrilled that they no longer have to go to private homes or venture out into neighborhoods” to get pot.

In emailed statements, the Treasury and Justice Departments said that their earlier guidance was still being applied. But banking and legal experts say the Trump administration has yet to lay down clear markers on this area of policy.

Officials in Uruguay are hopeful that American lawmakers will pass legislation allowing banks to do business with marijuana sellers in states and countries where it is regulated. Representative Ed Perlmutter, Democrat of Oregon, introduced a bill in April that would do that, but marijuana advocates say they do not expect a prompt legislative change.

“It is ironic that laws aimed at fighting drug trafficking and money laundering have created a roadblock for a system that intends to do just that,” said Hannah Hetzer, an analyst at the Drug Policy Alliance, which supports decriminalization of marijuana. “Uruguay is creating a legal market that displaces the illicit marijuana market.”

Mr. Bachini, the pharmacist, said he had not yet heard from his bank. But if it threatened to shut down his account, he said, he would not think twice about giving up marijuana sales.

“This pharmacy has been around for 30 years,” he said. “I’d just stop until this issue with the United States is resolved.”
 
Ah, that hotbed of stoner-dude liberalism....The American Legion...is even calling for access...and basically telling ole' Jefferson to go fuck himself. Which is actually something I would rather enjoy doing myself.

American Legion To Feds: Increase Veterans’ Medical Marijuana Access


One day after President Trump addressed its national convention, the largest military veterans organization in the country is calling on his administration to allow government doctors to recommend medical marijuana through the U.S. Department of Veterans Affairs (V.A.).

“More than half the states in the union have passed medical marijuana laws to date,” reads a resolution adopted Thursday by the American Legion, which has more more than 2.4 million members. “The American Legion urge the United States government to permit VA medical providers to be able to discuss with veterans the use of marijuana for medical purposes and recommend it in those states where medical marijuana laws exist.”

Under a current internal V.A. administrative directive, federal policy is “to prohibit V.A. providers from completing forms seeking recommendations or opinions regarding a Veteran’s participation in a State marijuana program.” That policy technically expired on January 31, 2016, but it remains in effect in practice until the department institutes a new one replacing it.

Last month, Veterans Affairs Sec. David Shulkin announced that a new directive is in the final stages of internal review. While it is not known what exactly it will say, he wrote in a letter to a member of Congress that it would “maintain the same policy” as the prior one.

Shulkin has on several occasions indicated that he sees marijuana’s medical potential but feels constrained by current federal laws.

During a briefing at the White House in May, Shulkin said that state medical cannabis laws may be generating “some evidence that this is beginning to be helpful, and we’re interested in looking at that and learning from that.” But “until time the federal law changes,” he added, “we are not able to be able to prescribe medical marijuana for conditions that may be helpful.”

In an appearance in June, he said, “From the federal government point of view, right now we are prohibited by law from doing research on it or prescribing it… We are not going to be out there doing that research or prescribing these different medicinal preparations unless the law is changed.”

In a separate June interview, he said that it is “not within our legal scope to study that in formal research programs or to prescribe medical marijuana, even in states where it’s legal,” adding, “if a law change at the federal level is appropriate, that could happen.”

It’s true, as Shulkin says, that federal law prevents doctors at the Department of Veterans Affairs from prescribing medical cannabis. But no doctor in the country — V.A. or not — can do so, since prescription if a federally-regulated process. In the 29 states with comprehensive medical cannabis laws, physicians instead recommend it to patients.

Federal law doesn’t actually block V.A. doctors from filling out paperwork for veterans who wish to participate in those state programs; the only thing standing in the way is the department’s own internal policy, which the V.A. secretary can change.

Shulkin, who previously served as V.A.’s undersecretary of health in the Obama administration, wrote in a letter last year that he “wholeheartedly agree that VA should do all it can to foster open communication between Veterans and their VA providers, including discussion about participation in state marijuana programs… I recognize that the disparity between Federal and state laws regarding the use of marijuana creates considerable uncertainty for patients, providers, and Federal, state, and local law enforcement personnel.”

While many veterans use medical cannabis to treat physical pain or post-traumatic stress disorder (PTSD) associated with their war wounds, they are currently forced to seek recommendations from outside doctors instead of from the V.A. physicians who know their medical histories. That process can be expensive, time-consuming and confusing for veterans.

The new American Legion resolution, adopted at the organization’s national convention in Reno, builds off a similar measure it approved last year calling on the federal government to reschedule cannabis.

“The American Legion urge Congress to amend legislation to remove Marijuana from schedule I and reclassify it in a category that, at a minimum, will recognize cannabis as a drug with potential medical value,” the earlier measure reads.

Earlier this year, top American Legion officials published an op-ed laying out the group’s case for reform.

“The opioid epidemic that continues to grip veterans is yet another reason to ease the federal government’s outdated attitude toward America’s marijuana supply. The Trump administration should lead a new effort to combat opioid abuse, and it should include the elimination of barriers to medical research on cannabis,” they wrote. “The result, potentially, could provide a non-addictive solution to the most common debilitating conditions our veterans — and others in society — face… Cannabis’ Schedule I listing is disingenuous given the fact that the federal government cannot produce any research or evidence justifying its classification – which significantly hampers medical research into the therapeutic aspects of the drug. It’s a classic Catch-22.”

The new resolution was approved by the American Legion’s Ohio department last month, and sailed through the national convention with little debate and only minor text changes in committee.

Also at the convention, attendees saw a presentation from Dr. Sue Sisley, who is conducting a large-scale trial on medical cannabis’s role in easing PTSD symptoms.

“This is a crucial next step for the American Legion after the first cannabis resolution passed last year. Enabling V.A. physicians to write medical cannabis recommendations for appropriate veteran patients is essential,” Sisley told MassRoots in an interview from the convention in Reno. “Veterans deserve safe access to lab tested cannabis in legal states.”

The powerful veterans group’s new call for increased medical cannabis access comes as Congress is considering the V.A.’s annual budget, through which some lawmakers are pushing the department to allow its physicians to issue medical marijuana recommendations.

Last month, the Senate Appropriations Committee voted 24 to 7 to approve an amendment to prevent the V.A. from spending money to enforce its existing ban preventing government doctors from filling out forms for veterans to qualify for state medical cannabis laws.

But while the full House of Representative voted 233 to 189 for a similar measure last year, Congressional leadership blocked a vote on the amendment in that chamber last month.

However, the veterans access issue isn’t necessarily dead for the year, even if Shulkin doesn’t make changes administratively through a new policy.

Advocates hope that because the provision preventing V.A. from enforcing the existing ban was inserted into the Senate’s version of the department’s funding legislation with such a strong bipartisan vote, the conference committee that later merges the two chambers’ bills together into a single proposal will adopt the language.

But a conference committee stripped the veterans cannabis provision out of last year’s bill even though it had been approved by strong bipartisan majorities in both chambers. This year, there won’t even be a House vote on the measure.

But the American Legion’s expanded position, given that it represents so many veterans and garners respect from federal officials — both Shulkin and Trump spoke at the convention this week — should provide a boost to efforts to convince Congressional leadership to allow the recommendation provision to become law this year.


“Year after year, we’ve never been able to pass the ‘veterans equal access amendment’ at the federal level,” Sisley said. “But with the full weight of the American Legion behind this next round of legislation, I know we can finally get this approved! I’m optimistic this will be a game-changer.”

Current funding for the federal government runs out on September 30, so decisions on provisions for Fiscal Year 2018 funding will likely be made soon, though there is a chance Congress will simply enact a short-term extension of current funding levels and policy riders to give itself more time to finalize legislation covering next year.

Congress could vote on several marijuana amendments next month, including proposals to allow cannabis businesses to access banks and to protect state laws from federal interference.
 
Either this will end up in courts between the states and this so-called National Marijuana Initiative (there ain't NO fucking initiative on MJ coming out of the Feds...sigh) or, if the states do provide HIPAA related data, then both the states and the Feds will be in court being sued by individuals whose privacy rights were violated.

Now, I don't like Trump....course I don't like Clinton (or Sanders...or Warren) either. But that fat fuck with the bad haircut needs to get his White House following policy that he set and not let all of these drug cold warriors go off reservation. He has said he supports states rights, the Republican party says they support states rights....if so, then they need to put that view into fucking ACTION as policy. Huh...I feel much better now.


White House anti-drug office asks Mass. for medical marijuana data

Dan Adams Globe Staff August 25, 2017


For more stories on the marijuana industry, sign up for our newsletter, This Week in Weed.

An arm of the White House’s antidrug office has asked Massachusetts and several other states where medical marijuana is legal to turn over information about registered patients, triggering a debate over privacy rights and whether state officials should cooperate with a federal administration that appears hostile to the drug.

Dale Quigley, deputy coordinator of the National Marijuana Initiative, or NMI, has asked Massachusetts health officials for data on the age, gender, and medical condition of the state’s approximately 40,000 registered medical marijuana patients. Quigley is a former police officer in Colorado with a long history of speaking out against legalization.

The NMI is part of the federal High Intensity Drug Trafficking Area initiative, a law enforcement effort directed by the White House’s Office of National Drug Control Policy.

In an interview, Quigley said the data are for a routine research project, in which he is looking for any correlation between how strictly states regulate medical cannabis and the rates of marijuana use among different age groups within the general public in those states.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.

He insisted that he is not seeking to identify patients and that his work doesn’t signal imminent changes to the current hands-off approach by the federal government to state-regulated medical marijuana operations.

“There are no black helicopters warming up in the bullpen,” Quigley said. “I have no idea where this is going to take us yet.”

But medical marijuana proponents said the mere notion that the Trump administration is nosing around medical marijuana could scare off patients, sending them to the black market for cannabis instead of registering with state-run systems that ensure medicines are tested for potency and safety. Patients did not consent to their data being used by the National Marijuana Initiative, they said, and can’t be sure their personal information was kept private.

“We must protect patients’ anonymity and comfort in obtaining medical cannabis without feeling like they’re being watched,” said Beth Collins, senior director of government relations and external affairs at Americans for Safe Access, a national medical marijuana advocacy group. “They’ll see this story and say, ‘Oh, the feds are going to know I’m a patient,’ and stay away. It’s an access issue.”

Some of the 29 states with medical marijuana programs already publish the data sought by Quigley on their websites. Massachusetts does not, but the state Department of Public Health, which regulates medical cannabis here, has provided Quigley with data on the genders and ages of its registered patients, saying that information is a public record.

That information does not identify patients by name. However, the department is still evaluating whether it should respond to Quigley’s request for a list of the medical conditions that prompted patients to register with the state. Some patients have rare ailments, and DPH officials are concerned it may be possible to use that data to identify them.

“Protecting patient privacy is a major consideration of our continued review,” a DPH spokesman said in a statement.

Massachusetts law prohibits DPH from disclosing identifying information about registered patients in most cases. To comply, and to guard against the use of sophisticated software that can correlate seemingly anonymous information with real-world identities, officials said they “blurred” some numbers provided to Quigley. For example, if there were only a handful of medical marijuana patients of a given age — say, one or two 90-year-olds — DPH’s spreadsheet doesn’t include the precise number but instead indicates only that were fewer than seven 90-year-olds.

The leaders of the Massachusetts Patient Advocacy Alliance, which sponsored the 2012 ballot measure legalizing medical cannabis in the state, said changes over time to the state’s registration process mean the data sought by Quigley will be incomplete.

“There is potential for incredible studies by real medical researchers,” said Nichole Snow, the group’s executive director, “but we want that data to be credible and accurate and also confidential. I think the patients of Massachusetts would feel this is an intrusion.”

Regulators in several other states where medical marijuana is legal, including Connecticut, Rhode Island, and Vermont, said they were evaluating which data they could legally provide to Quigley. Officials in Maine noted that their registry is voluntary and said the state doesn’t collect demographic data from patients who sign up.

For now, the US Department of Justice is operating under congressional restraints and an Obama-era edict that essentially prohibit federal law enforcement actions against state-regulated medical marijuana operations that don’t contribute to interstate trafficking or public health and safety problems.

But Trump’s attorney general, former US senator Jeff Sessions, is a longtime antidrug hard-liner. He has sought to remove constraints on marijuana investigations, and he recently sparred with governors of legal-marijuana states who said he used flawed and outdated data to argue that legalization has caused a spike in emergency room admissions and drug trafficking.

The agency that Quigley works for reports directly to the White House, not to Sessions. But advocates worry that the data Quigley is collecting could eventually be used — or misconstrued — by US officials to help build a case for a crackdown. And they also questioned his qualifications and motivations, noting that his expertise is in law enforcement, not research or statistics, and that he has given talks around the country decrying marijuana legalization.

“He’s obviously biased,” Collins said, “and if research isn’t done right, it can show whatever he wants it to show. Why isn’t a researcher doing it? That’s a red flag to me right away.”

Moreover, various state medical marijuana programs have existed for different lengths of time, and collect different levels and types of data. That, Collins and others said, would make it difficult for even a sophisticated researcher to reconcile the numbers and produce a valid, “apples-to-apples” comparison.

Quigley himself acknowledged he is skeptical of loosening prohibitions on marijuana.

“I’ve not seen much good come out of legalization,” he said. “When you make something that has no sense of risk or harm attached to it widely available, use rates are going to go up.”

Governor Baker Cautious About Federal Medical Marijuana Requests



 
What...is this lady ole' Jefferson's long lost German cousin? Or maybe they are a match made in heaven and we should ship ole' Jefferson over to her. They can both practice saying "Ve vill crush all cannabis". At least she hasn't claimed its a Jewish plot against the German people. Where do they find people like this. Why has Merkel put up with this nut case?

Do you think she looks like Eva Braun?


German Drug Czar Attacks US Cannabis Lobby
upload_2017-8-29_12-24-30.jpeg


he Drug Czar of the Federal Republic of Germany, Marlene Mortler (CSU), verbally attacked the U.S. cannabis lobby during a presentation of the government’s 2017 Drug and Addiction Report. During a recent press conference, Mortler explained that “U.S. cannabis companies are doing a great deal of business in Germany.”

The CSU-representative added that the wealthy nation of Germany was a desirable market for hedge funds — especially from the USA. According to Mortler, these investors lurk in wait for Germany to the expand the market opportunities.

She also said that since the legalization of medical cannabis in Germany, U.S. companies have touted high expectations regarding Germany’s business potential. According to Mortler, the cannabis lobby now has more direct access to decision-makers than the alcohol or tobacco lobbies, and can effectively engage younger generations through the social media.

The Drug Czar’s Poor Record
During the presentation of this year’s report, the Drug Czar sought out culprits to blame for her poor performance record, which showed a rise in drug-related deaths in Germany for the fourth year in a row. In her home state of Bavaria, where there are hardly any aid programs to help drug addicts, the numbers are increasing immensely.

When it comes to cannabis, Mortler is convinced that the plant’s increasing popularity is the direct result of activism and lobbying efforts. She has continuously declined opportunities to speak with cannabis activists — the “Hemp-Lobby” as she put it — ignoring any possibility of a direct exchange of factual arguments. No interviews, meetings, panels, not even a Skype-dialogue has occurred since she took the role of Drug Czar in 2013. Mortler does not talk to or with her drug policy opponents or cannabis consumers; instead, she talks about them.

In 2016, Mortler complained that Germany’s cannabis users had started a kind of digital war against her. Activists had launched “Mortler off” T-shirts, published a related Facebook page, and promoted a petition for her withdrawal on Change.org. But the CSU leader is hardly diplomatic when it comes to cannabis. She once advised the well-known German rapper Thomas D. on Facebook not to publicize his opposing opinions on cannabis, acerbically asking whether the highly reputed artist “if he had smoked too much.”

Even the former financial economist, green politician and founder of the German Hemp Association, Georg Wurth, was called a “gambler and player” by Mortler. He’s never given her a harsh word.

Dubious Numbers to Continue Prohibition
In Mortler’s criticism of the U.S. cannabis lobby and the situation in Colorado, the staunch cannabis opponent skates on thin ice when asserting that the consumption among young people has surged in Colorado since the state regulated cannabis. The source of her ignorance stems from the questionable figures of the “Rocky Mountain High Intensity Drug Trafficking Area” (RMHIDTA). The report does not address the Colorado Ministry of Health’s official report on the effects of legalization. In contrast to the RMHIDTA’s alleged report of increased cannabis use among adolescents, the state’s Health Department released a study in June, finding that cannabis use among teens has not increased since legalization and remains in line with the national average.

Mason Tvert, the current communications director for the Marijuana Policy Project in Colorado, commented on the windy figures and the work of the RMHIDTA 2016 for Vice magazine:

“It’s kind of laughable, but unfortunately it gets taken seriously by some,” Tvert said of the Rocky Mountain HIDTA report. “This is an agency that, much like the DEA, is living in the 1930s when it comes to marijuana.”

Germany Drug Commissioners also claim that today’s cannabis products are much stronger and therefore more dangerous than they were in the 1970s — this is also demonstrably wrong. In the 1970s, Europeans almost exclusively smoked hashish, which contained a similar THC content to today’s most potent indoor flowers. The Federal Criminal Police Office confirmed this fact in 2004 when the rumor of highly-potent GMO-cannabis made national headlines for the first time. Additionally, Mortler’s predecessor, Mechthild Dyckmans, confirmed those findings in 2012:

  • The active substance content has fallen overall since 1997 and has not increased ever since,
  • No figures are available that are older than 30 years to compare with the current ones,
  • Only a short-term increase in the late 1990s could be established.
Last but not least, highly potent cannabis is no more dangerous than the less potent varieties, as long as the consumers are aware of its THC content.

Criticism That Ennobles
Mortler, an expert on agricultural policy, lacked drug policy experience at the time of her inauguration. Her perfidious and often difficult-to-believe tactics, just as in the “Pharmacy Review” of January 2015, may be doing more to help pro-cannabis efforts in Germany:

PR: Would a general prohibition on advertising for alcohol and a uniformly high tax rate on alcoholic beverages prevent alcohol abuse among young people better (than the current law)?

Mortler: If you forbid everything, do you think a child says: ‘Yes, mama, you’re right.’? Our country does not want and can not ban anything. Children and young people must be convinced – through education and role models.

PR: Do you believe in the efficiency of bans when it comes to cannabis prohibition?

Mortler: Cannabis is an illegal drug.

Unfortunately, the poor defender of Germany’s drug policy will leave office after the coming elections in October. Since the position of the Drug Officer is not very popular and has never been occupied by the same person for more than one legislative period, Mortler will likely lose the opportunity to provide such a weak case against legalization, as she has for years. In Germany, a pseudo-liberal Drug Czar could do more to slow down the movement’s intake and influence than a drug-related hardliner with moderate stances, representing long-outdated science and facts.
 
Israeli and Canadian Firms Partner for Cannabis Production Plants in 4 U.S. States

Israel-based medical cannabis company Panaxia has partnered with Canada’s Bioceutical Corporation to set up four medical cannabis production plants in Arizona, Nevada, Maryland, and Massachusetts, according to a report from Globes.Last year, Panaxia set up a similar production facility in New Mexico, which went online in March.

The agreement will see Bioceutical Corp., which is traded on the Canadian Securities Exchange, will finance the project, provide the cannabis, and market the products. Panaxia will build and manage the plants and all of the other product inputs, save for the cannabis. According to the report, Bioceutical Corp. is already actively marketing products in Nevada and Arizona, and the two firms will jointly enter Massachusettsand Maryland.

Panaxia Managing Partner Advocate Assi Rotbart indicated that the company is already producing 10,000 units of sublingual tablets, oils, lozenges, and an inhaler per week at the New Mexico facility. Rotbart said the firm partnered with G.W. Pharma and Ultra Health in that venture.

“We discovered that we had incorrectly assessed the strength of the demand. The plant is now operating at full capacity… and we are in the process of expanding it,” he said in the report. “The factories that will be built under the new agreement will be much larger.”

Dr. Dadi Segal, founder and chairman of Panaxia, said the firm is also preparing to open a cannabis production facility in Israel under federal reforms.
 
According to the report, Bioceutical Corp. is already actively marketing products in Nevada and Arizona, and the two firms will jointly enter Massachusettsand Maryland.

I believe that this must be referring to a processor license in Maryland. But I question this statement:

Bioceutical Corp., which is traded on the Canadian Securities Exchange, will finance the project, provide the cannabis

Unless Biceutical is one of grower license winners in MD, they ain't supplying no cannabis as it must all be traced from seed as grown in a licensed MD facility.

Not really sure what they are saying here nor can you tell from looking at the name of license winners who's behind them as these are often teams of companies trading under another name.
 

Learn from Colorado’s mistakes, says former cannabis czar

Andrew Freedman reflected on lessons learned in the first years of legalization at the National Cannabis Summit in Denver


If he had to do it all over again, Colorado’s former marijuana czar would approach cannabis legalization by gathering loads more data, taking a calculated approach to edibles and including an even greater cohort of public health voices.

Andrew Freedman, now a consultant for states and cities trying to develop cannabis regulations, delivered the closing keynote speech Wednesday at the National Cannabis Summit, a three-day conference to explore best practices on approaching topics such as public health, safety, research, prevention and treatment efforts.

He told officials and researchers gathered in Denver that were he launching new legalization efforts he would focus data collection and analyses efforts on problematic use. He would also rethink home-grows, go slow on edibles, fund a glut of surveys and put tax revenue dollars toward public health needs instead of school construction, he said.

Public sentiment and grassroots movements are advancing legalization campaigns at light speed, leaving state regulators scrambling to build comprehensive and thoughtful policies on the fly, Freedman said. His hope is that others can learn from Colorado’s successes and its stumbles as it became the first state to regulate and tax the sale of cannabis for adult-use.

“There’s a lot that we did not achieve in Colorado that I think version 2.0 could achieve in other states,” he said.

Colorado made some missteps in the early stages of legalization, Freedman said, highlighting case studies on youth prevention and edibles.

First, Colorado “ran into a messaging problem” with youth marijuana use data.

After national data showed rates increased between 2013 and 2014, “we got berated,” Freedman said, because state officials — at the behest of public health data experts — proclaimed that the gains were not statistically significant. When the rates dipped from 2014 to 2015, officials were reassured of the need to wait before having accumulated enough years of data to develop conclusions.

“We have to keep patient with data,” Freedman said.

Related stories
Colorado also missed a mark on youth prevention campaigns, he said, noting the push-back from schools and the marijuana industry on the Colorado Department of Public Health’s “Don’t Be a Lab Rat” teen pot use campaign. Boulder Valley School District and others chastised the effort for being too heavy-handed and stigmatizing.

Colorado officials regrouped and later found success with campaigns such as “Protect What’s Next,” which highlighted future goals and potential while providing quick data points on health effects and consequences of underage marijuana use, as well as the state’s “Good to Know” campaign that provided resources for parents and teachers to discuss with children and teens.

Another win, he said, was the allocation of marijuana tax revenue toward behavioral health hires in schools.

On the edibles front were several troubling stories and trends, including the death of a college student who ate six times the recommended amount of a marijuana edible, and increases in emergency room visits and poison control calls, he said.

Colorado Department of Public Health and Environment’s move to ban edibles was ultimately unsuccessful, but Freedman saw it as a good message: “let’s scale back and start working our way back up,” he said.

The state eventually addressed some concerns about edibles by instituting labeling and packaging requirements and barring shapes such as animals, people and candy.

However, conclusions and solutions that took 18 months or more could have been achieved in quicker fashion, he said.

There are “large repository of good data sets that are out there not really speaking to each other,” he said.

For example, the seed-to-sale system could have been better mined to see that edibles were selling more quickly in the recreational market than in the medical market and the concentration of those sales were in tourist-heavy areas.

Noting that revenue should not be a paramount focus of legalization, Freedman said that marijuana tax revenue would be better spent in areas of public health and public needs rather than “pet projects” such as education and transportation.

“I’m of the mind that most of the pet projects are wrong,” he said.

As Colorado quickly learned, earmarking $40 million for school construction projects resulted in public confusion that marijuana money was solving school funding woes — when it barely put a dent in the issues.

The money instead could be allocated for programs — including housing for the homeless — that don’t receive a lot of funding from other sources and instead would show a measurable impact, he said.

Freedman hammered on the need for the inclusion and participation of a variety of public health officials throughout the legalization process as well as a need for more robust data and research.

The calls for data and research were themes throughout the three-day conference, sponsored by the National Council for Behavioral Health, Advocates for Human Potential and the Addiction Technology Transfer Center.

On Tuesday, Susan Weiss, director of extramural research for the National Institute on Drug Abuse, lamented reports that an expansion of federal marijuana research efforts was halted by the Department of Justice. Such a move would leave the University of Mississippi as the sole supplier of marijuana for research purposes.

“NIDA would be really, really happy if there were other growers,” she said.

Weiss also expressed concern about how new legalization laws are outpacing research. Marijuana science is not influencing policy, she said.

That’s a problem when giant question marks hover over long-term outcomes, the potential negative effects on developing brains and bodies, and the potential beneficial therapeutic possibilities for the plant’s components, she said.

“This is heartbreaking because this is happening now and we should be learning from it,” she said, adding that, “the federal/state differences are really not helpful in moving this along.”
 
So, I don't really wish anyone physical harm....and I try very hard to adhere to that no matter the provocation. However, if this self-righteous asshole, Sabet, dropped dead tomorrow, I don't believe I would shed a single tear.

The good news is that he is losing and losing big.


Anti-legalization group urges feds to “systematically shut down” cannabis industry
Legal marijuana states "are inviting shift in enforcement," says Smart Approaches to Marijuana leader


Jeff Sessions has more reading about marijuana regs on his desk.

This month, governors from Alaska, Colorado, Oregon and Washington, the first four states to legalize recreational marijuana, each sent letters to the attorney general defending their respective regulatory regimes, designed to uphold the Cole Memo. That Obama-era memo outlined law enforcement and financial oversight priorities for states that have legalized marijuana for medical or recreational use.

On the fourth anniversary of the memo, Smart Approaches to Marijuana (SAM), a nonprofit group opposed to marijuana legalization, announced it had sent a report to Sessions and other lawmakers detailing how those states have failed to live up to the responsibilities outlined.

Based on its report, “The Cole Memo: 4 Years Later,” SAM recommended that Sessions “take measured action to successfully protect public health and safety. Limited federal resources should be used to target the big players in the marijuana industry who are circumventing (Department of Justice) guidance and state regulations.”

Related stories
In a phone conference Wednesday, Kevin Sabet, SAM’s president, went further, saying, “We do not want individuals prosecuted — we want the industry to be accountable. This industry — starting from the top — should be systematically shut down.”

The SAM report says that Colorado, Oregon and Washington have failed to comply with seven of the eight guidelines of the Cole Memo, which include preventing access to minors, flow to other states, drugged driving and growing of the plant on federal lands. As a result, Sabet said, the states “are inviting a shift in enforcement.”

In the recommendations from the report SAM says cannabis businesses “are pocketing millions by flouting federal law, deceiving Americans about the risks of their products, and targeting the most vulnerable. They should not have access to banks, where their financial prowess would be expanded significantly, nor should they be able to advertise or commercialize marijuana.”

The SAM report echoes some of Sessions’ own claims in recent letters to the governors of the four states, stating, “States with legal marijuana are seeing an increase in drugged driving crashes and youth marijuana use. States that have legalized marijuana are also failing to shore up state budget shortfalls with marijuana taxes, continuing to see a thriving illegal black market and are experiencing an unabated sales of alcohol… State regulatory frameworks established post-legalization have failed to meet each of the specific DOJ requirements on controlling recreational marijuana production, distribution, and use.”

Story continues below video
Cannabist interview with SAM’s Kevin Sabet in July 2015:
newsinconebyone.png

RAW video: Get inside the mind-set of anti-legalization group Project SAM
Denver Post

23881771.jpg

Also on the call announcing the SAM report was John Jackson, chief of police for Greenwood Village in Colorado. The commercialization of marijuana has “offended” even people who voted for legalization, he said.

“People see billboards, articles in the newspaper, internet ads and say, ‘I voted for it, but this isn’t what I voted for. This isn’t what I thought was going to happen with the dabbing and access to minors,'” he said.

In outlining its case against Colorado’s marijuana regulatory regime, The SAM report cited multiple news stories from The Cannabist and The Denver Post, including:

Former marijuana enforcement officer, entrepreneur indicted in massive Colorado trafficking ring
Exclusive: Traffic fatalities linked to marijuana are up sharply in Colorado. Is legalization to blame?
Hiker finds illegal marijuana grow worth $7 million in San Isabel National Forest
Crime rate in Colorado increases much faster than rest of the country
Pot problems in Colorado schools increase with legalization
More Colorado pot is flowing to neighboring states, officials say
 
The Cannabis Caucus Continues To Fight For Progress In Washington D.C.
On Thursday, February 16, 2017 a few bi-partisan legislators launched the Congressional Cannabis Caucus. Representatives Dana Rohrabacher, a Republican from California; Earl Blumenauer, a Democrat from Oregon; Don Young, a Republican from Alaska; and Jared Polis, a Democrat from Colorado launched the first of its kind caucus at a press conference in Washington DC. Watch the press conference below.

The goal of the caucus, “to harmonize federal laws that prohibit medical and recreational cannabis use with state laws that permit it” was expected by most to be an uphill (pun intended) battle. Specifically, they want to begin effecting change by increasing medical research into cannabis and changing regulations on banking and taxation for cannabis businesses. But to be clear, the caucus intends to work to ensure individual states have rights to these pursuits, their intention is not to achieve federal legalization.

And the starting team to pull this off looked strong. Technical420 has often mentioned cannabis actually becoming one of the few uniting issues in American politics, and the cannabis caucus proved that true. Having representatives from both sides of the aisle and from the two most widely regarded cannabis states (Colorado and California) certain seemed to imply leverage, influence, and exposure.

The timing couldn’t have been more crucial either. Launching shortly after the appointment of prohibitionist Jeff Sessions as Attorney General, the caucus was shaping up to look exactly like what the country needed to counter the Alabama gremlin.

How successful has the caucus been? How do we even define success? We certainly can’t hold them accountable for marijuana not being federally legal, it’s not even their goal. Baby steps (or at least small adult steps) right? In the stew of Washington DC mistrust and backroom deals, can we be sure these guys really have marijuana’s best interest at heart? Let’s take a look at what they have done individually for marijuana and what the caucus as a whole has achieved. The most rational judgement may come from dissecting their achievements in relations to their goals.

Dana Rohrabacher (R-CA) and Earl Blumenauer (D-OR), the two founding members of the caucus, both have respectable achievements even before they started the caucus. Congressman Rohrabacher coauthored the Rohrabacher-Farr Amendment, which was passed by the 113th Congress in 2014. The amendment prevented the Department of Justice from using its funding to challenge states that have approved medical cannabis laws. In 2017, he was widely regarded for ensuring its extension – which was widely seen not only as continuing protection for pro-marijuana states, but as a direct rebuke of Jeff Sessions and his prohibitionist policies.

Meanwhile, Earl Blumenauer (D-OR) supported the Oregon ballet measure 91 in 2014, which legalized recreational cannabis in Oregon.

Additionally (and of course), Rohrabacher endorsed the Adult Use of Marijuana Act, which legalized recreational cannabis in California in 2016. But he took it a step further when he acknowledged using medical cannabis to treat his arthritis!

Props, fellas. But you’re only as good as your last success. What success (or attempts at success) have been made since the caucus formed?

That’s very debatable.

The caucus did add another member, representative Ed Perlmutter, a Democrat from Colorado. Not too impressive, especially considering over 30 states now have legal or medical marijuana of some kind.

We wouldn’t be concerned with who was a member as long as they were advancing pro-marijuana legislation though. There are currently 22 pieces of marijuana legislation before the 115th U.S. Congress – more than ever in history.

Yet, this amount of legislation may be a hindrance to the pro-marijuana agenda and a strike against the Cannabis Caucus. Of the 22 pieces of legislation, only 6 were introduced by Cannabis Caucus members and half were introduced by Representative Blumenauer himself.

The caucus seems to be lacking effectiveness in organizing what is clearly a large amount of pro marijuana support behind a few bills. When senators have competing pieces of similar legislation, it often acts as a splintering or divisive point rather than a uniting one. Representatives score major political points in the districts or states if their piece is voted into legislation, and the often receive campaign funding based on the legislation they have introduced.

The Cannabis Caucus could be much more effective in uniting the movement so to act as a unified front, which is much more favorable to the current self-serving pot popularity contest being ran as individuals.

Let’s also consider the lack of traditionally red states that could be brought into the fold – Kentucky and North Carolina, for example, are growing thousands of acres of industrial hemp this year. Often their concerns align directly with states pursing marijuana: banking, federal crack downs, interstate commerce, etc. It seems they would make valuable allies, and yet they are completely absence not just from the caucus, but from each-others conversations and bills.
 
As prohibitionists spread false accusations, hard data prove legal cannabis is safe and has overwhelming acceptance
As prohibitionists spread false accusations, hard data prove legal cannabis is safe and has overwhelming acceptance while strengthening the economy through job growth and tax revenues

The Cannabis Business Alliance (CBA) has released a statement in response to a recent report by anti-legalization organ SAM that attempts to claim that states that provide legal cannabis have failed to comply with the Cole Memo.

“States such as Colorado diligently uphold the responsibilities outlined in the Cole Memo and are working stringently to advance regulatory and compliance frameworks as a blueprint for other states that have seen the benefits of removing cannabis profits from the pockets of drug cartels and into schools and public health programs,” said Kevin Gallagher, Executive Director of the Cannabis Business Alliance. “Colorado is doing it right, and policymakers in states that have not yet come online are watching the Centennial State closely as a successful model for stimulating local economies while keeping constituents safe. SAM’s frivolous claims are just another prohibitionist attempt to halt the positive strides of an industry that has been proven to be an economic force in states where marijuana is legal,” Gallagher said.

Colorado’s cannabis industry has taken every precaution to ensure public health and safety, and statistics verify the state’s overwhelming success. Legalization of adult-use marijuana has not encouraged crime. In fact, Colorado's property crime rate fell by 5 percent between 2012 and 2015. Since 2009, both property and violent crime rates have fallen by 3 percent and 6 percent respectively. Legal cannabis has not resulted in an increase in youth use. A report from Substance Abuse and Mental Health Services Administration (SAMHSA) released in December 2016 found teen marijuana use fell sharply in Colorado in the years 2014 and 2015, after the opening of that state's recreational marijuana market, federal survey data show, confirming that instituting a legal cannabis industry reduces youth access, similar to alcohol regulations. According to an NIH report also released December 2016, marijuana use declined among 8th and 10th graders and remains unchanged among 12th graders compared to 2011, despite the changing state marijuana laws and past-year use of marijuana is at its lowest level in more than two decades among 8th and 10th graders. Organizations such as the Marijuana Education Initiative (MEI) have developed cannabis specific educational curriculum with a progressive and sensible approach to prevention and intervention. Since 2015, the MEI has worked directly with schools and students to promote a balanced and informed understanding of the effects of youth marijuana consumption.

The SAM report claims that “businesses target many of the marijuana products they sell toward kids, such as pot candies, cookies and ice cream.” However, Colorado’s rules for infused products mandate that the products cannot be shaped like animals or be in packaging designed to appeal to children. As of October 1, 2016, regulations also require all packaging as well as cannabis-infused products be marked with a “Universal Symbol” - a diamond enclosing the notations “!THC” or “!THCM”.

“Between child-resistance, prohibited advertising of cartoon characters, opaque packaging, and warning statements, Colorado infused products manufacturers are doing more than any other industry to make edibles less appealing and accessible to children,” Gallagher added. “Additionally, when a child does end up in a hospital due to accidental ingestion, it is more likely from edibles that were homemade by the parents, rather than edibles that were purchased in a legal dispensary and provided in child proof packaging. CBA stresses that parents should treat their cannabis as they would any other product that should not be accessible to children under the age of 21: lock it up and keep it out of sight.” Legal cannabis products are less likely to be accidentally ingested by kids than dish detergent packets, diaper rash cream, and even alcohol-infused chocolates. With more than five million infused product units sold each year and diminishing cases of accidental ingestion, the industry feels strongly that it is headed in the right direction. Colorado law mandates that children under the age of 21 are not allowed to step foot into a dispensary, unlike drug dealers who do not card their customers, and expose under age children to black market marijuana as well as deadly drugs such as heroin and designer drugs that are killing youth at an alarming rate. CBA fully supports full enforcement against black market marijuana operations.

Colorado has one of the country’s fastest growing economies, due in part to the legalization of marijuana. Colorado marijuana tax revenues greatly exceed original estimates of $70 million per year. Collections of $56 million in 2014 grew to $113 million in 2015. In 2016, the state reported roughly $1.1 billion in legal sales with over $200 million collected in tax revenue. Marijuana tax money has been used to improve a wide range of community programs and services, funding everything from school construction and public health and law enforcement to substance abuse prevention and fighting homelessness. As of January 2017, more than 23,000 people in Colorado now have full-time jobs because of the legalized marijuana industry, and Colorado’s unemployment rate has consistently posted at around 2.3 percent, often ranking the lowest in the country, and the lowest rate in Colorado since at least 1976.

“It is important that states take a thoughtful approach to marijuana taxation. If the taxes are too high, the black market flourishes, too low and the state misses significant revenues for public priorities. Colorado leads by example, taking power and money out of the hands of drug cartels and putting funds directly into state coffers,” Gallagher continued.

The SAM report also attempts to falsely link legalized marijuana with an increase in traffic incidents. “There is no clear evidence linking legalized marijuana to an increase in traffic incidents or fatalities in Colorado,” Gallagher said. “Prior to 2014, proper coding did not designate cannabis use in traffic incidents, and this issue persists even to this day, with many studies lumping cannabis use with prescription and illicit drugs such as opioids, and there are no standards for testing crash victims.”

While opposition groups like SAM aim to bring the enormous benefits of marijuana to a screeching halt, legalized cannabis continues to offer unparalleled medicinal options for patients including veterans suffering from PTSD, as well as women--who experience PTSD exponentially more than men--often as a result of domestic abuse. Cannabis has also been effective for children with debilitating conditions such as epilepsy and spastic quadriplegic cerebral palsy. Pulling back in any way would not only prohibit those who need marijuana most from getting it, but also go against the will of the American people.

More Americans are in favor of legalized marijuana than ever before. The latest Harvard-Harris Poll survey found that 49 percent of Americans believe marijuana should be legalized for both medical and recreational use and 37 percent believe marijuana should be legalized for medicinal purposes only, meaning that 86 percent of respondents support legalization in some form. Only 14 percent of respondents believe marijuana should be illegal.

Legal marijuana can also help to address the opioid epidemic, which has recognized by the current administration as a widespread national epidemic. The opioid epidemic kills 91 Americans every day, according to the Centers of Disease Control. Fortunately, a wealth of new research points toward cannabis as a potential solution to prescription painkiller addiction. A study published in 2014 in the journal JAMA found that states with legal medical marijuana experienced a nearly 25 percent drop in deaths from opioid overdoses, compared to states that do not have legal medical marijuana.

“CBA maintains that cracking down on legal cannabis businesses merely pushes a safe, regulated, taxable industry with professionally produced, lab-tested products back into the black market. We highly encourage policy makers in emerging states to speak directly with people involved in Colorado’s cannabis industry regarding regulatory and compliance framework,” Gallagher concluded.
 

Sponsored by

VGoodiez 420EDC
Back
Top